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ABSTRACT

In my dissertation research we used use human wild type α-synuclein
gene expression using an adeno-associated viral vector (AAV9) that induced a
slowly progressive loss of dopamine (DA) neurons in the Substantia nigra (SN)
as one of our animal model of Parkinson’s disease (PD). It is our hypothesis that
neuroinflammation predisposes the brain to susceptibility to neurodegenerative
diseases. Thus we examined the progression of a PD lesion and examined the
manipulations of the immune system to understand further the inflammatory role
when we administered exogenous soluble fractalkine.
The specific etiology of neurodegeneration in PD is unknown, but the
inflammatory mechanisms and free radicals have been postulated to play a
central role. α-synuclein is believed to be the one of the main characteristic
associated with PD. It has been found inside saclike structures, called lewy
bodies. α-synuclein is believed to activate resident microglia worsening the
degeneration of the nigrostriatal pathway due to its aggregation. Aggregation
increases the production of reactive oxygen species (ROS) released from
microglia. The constant release of these factors and prolonged activation of
microglia could be the cause that leads to neurodegeneration in the SN.
Spirulina, a blue - green algae, has been shown to have anti-oxidant and
anti-inflammatory properties. For example, when rats received an intrastriatal

vi

injection of 6-OHDA and were fed a spirulina enriched diet for 4 weeks, there
was a significant increase in regeneration of DA terminals into the Tyrosine
Hydroxylase (TH) -negative zone of the striatum. This regeneration was
accompanied by a decrease in microglia activation as determined by
immunohistochemistry of major histo compatibility class II (MHC) (OX-6). This
suggests that decreases in microglia activation modulate the beneficial effects of
spirulina. Another important therapeutic tool we used was fractalkine as an antiinflammatory treatment. It is known that fractalkine levels are reduced in the
brain during aging. For this reason we administered exogenous fractalkine to 6OHDA model of PD to test the hypothesis that it improved the microenvironment
by reducing microglial activation.

vii

CHAPTER 1

INTRODUCTION

1.1 Progression of Aging
The aging process is very natural, it happens to all of us through our
individual lifespan. Since we are born we grow older and we are constantly
changing. Skin will loose its elasticity and sometimes we will see these signs as
deterioration or decline. There is a bigger problem that comes with aging and is
not the loosing of the hair or getting wrinkles but our physical and mental
deterioration. This deterioration is due to the fact that our bodies will not respond
like they used to. Regular physical activity, a balanced diet, social involvement,
moderate to no drinking, and no smoking, can significantly decelerate the aging
process. Sometimes even taking safe precautions we deteriorate, it is human
nature and completely normal. Scientists theorize that aging likely results from a
combination of many factors. Therefore, genes, lifestyle, and, disease can all
affect the rate of aging. The problem arises with neurodegenerative diseases;
they can put a dent in the normal aging process making it more uncomfortable.
Below many factors that are shared and seen in both aging and
neurodegenerative diseases will be discussed.
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1.1.1 Inflammation, microglia and aging in the brain
Increasing evidence associates aging and age-related diseases with
inflammation (Ye and Johnson 1999; Forsey, Thompson et al. 2003; Bodles and
Barger 2004). The key cellular event signaling constant inflammation in the brain
is the accumulation of reactive microglia in the degenerative areas (David,
Ghozali et al. 1997; Streit, Walter et al. 1999). Microglial cells are the resident
immune cells of the central nervous system; they constitutively express surface
receptors that trigger or amplify the innate immune response. These include
complement receptors, cytokine receptors, chemokine receptors, major
histocompatibility complex II and many others (Aloisi 2001). In the case of
cellular damage, they respond promptly by inducing a protective immune
response which consists of a transient upregulation of inflammatory molecules as
well as neurotrophic factors (Batchelor, Liberatore et al. 1999). This innate
immune response usually resolves potential pathogenic conditions. However,
when chronic inflammation occurs, prolonged activation of microglia triggers a
release of a wide array of neurotoxic products (Colton and Gilbert 1987) and
proinflammatory cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6),
tumor necrosis factor alpha (TNF). Elevated levels of IL-1, TNF and IL-6
have been found in the brains of aged animals (Gemma, Mesches et al. 2002;
Terao, Apte-Deshpande et al. 2002; Weindruch and Prolla 2002) and animal
studies have shown that increased levels of IL-6 in the hippocampus and
cerebral cortex are primarily from microglia (Ye and Johnson 1999). Scientists
have suggested that the increase in brain microglial activation may be one of the
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early events that lead to oxidative damage. Activated microglia are indeed the
most abundant source of free radicals in the brain and they release radicals such
as superoxide and nitric oxide (Chang and Liu 1999). Microglia derived radicals
as well as their reactive products, hydrogen peroxide and peroxynitrite, can harm
cells and these products have been shown to be involved in oxidative damage
and neuronal cell death in neurological diseases (Dringen 2005). Microglial cells
have efficient antioxidative defense mechanisms because they contain high
concentrations of gluthatione, the antioxidative SOD enzymes, catalase,
glutathione peroxidase, and glutathione reductase, as well as NADPHregenerating enzymes (Dringen 2005). However, when the production of
reactive oxygen species (ROS) is prolonged, the endogenous reserves of
antioxidants become exhausted and result in cell damage.
Microglia and dendritic cell activation that results from brain inflammation
has been increasingly associated with the pathogenesis of Parkinson’s Disease
(PD), as well as several other neurodegenerative disorders. Journals such as
Nature Neuroscience have devoted reviews and special issues on inflammation
and neurodegeneration recently, reinforcing the impact of this area on our current
thinking about neurodegenerative disease. Aside from the dramatic loss of
dopaminergic neurons associated with PD, it has been shown that the substantia
nigra (SN) is also the site of a robust glial reaction in PD patients and in humans
with MPTP (1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine). MPTP, which is a
neurotoxin that causes permanent symptoms of PD by destroying dopamine
neurons in the substantia nigra of the brain (Langston, Forno et al. 1999) and in
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response to -synuclein in both humans and animal models (Austin, Floden et al.
2006; Reynolds, Glanzer et al. 2008; Su, Maguire-Zeiss et al. 2008). Increased
numbers of microglia, and more specifically the presence of activated microglia
have been shown to be present in both early and late stages of the disease
(McGeer and McGeer 1997; Banati, Daniel et al. 1998; Mirza, Hadberg et al.
2000). Activated dendritic cells (DCs) and microglia appear to have a dual role in
that there is upregulation of both neuroprotective and neurotoxic factors. Studies
have shown that intracerebral implantation of microglia in rat models of PD has
been shown to improve rotational behavior and increase TH immunoreactivity.
Providing evidence of the beneficial effects of activated microglia (Lindvall 1991;
Ewing, Weber et al. 1992). On the other hand, the activation of DCs and
microglia can lead to neuronal death. It has been proposed that increases in
microglia may be one of the early events that lead to oxidative damage. As
mentioned previously, activated microglia produce a wide array of cytotoxic
factors, including ROS, pro-inflammatory cytokines, and nitric oxide. It is
postulated that manganese toxicity, which resembles PD in many respects, is
due to a microglia activation which, in turn, leads to the production of nitric oxide
and thus resulting in oxidative damage to neurons (Chang and Liu 1999).
It has been proposed that at least two activation states of peripheral DCs
and macrophages can be identified (Duffield 2003). Because microglia are the
macrophages of the brain, it is likely that these phenotypes apply to these cells
as well. The state induced by TH1 cytokines such as IL-1, IL-6, TNF, and the
CD40 ligand is referred to as “the classical proinflammatory state” by Duffield
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(2003) and “M1” by others (Mantovani, Sica et al. 2004). This state associates
with further production of other pro-inflammatory cytokines such as, ROS,
chemokines, and matrix metalloproteases, resulting in cell death of foreign
antigens and further inflammation. A second state of activation, “the alternative
activation state” is associated with the TH2 cytokine profile of IL-4, IL-10 and
TGF-1. When DCs and macrophages/microglia are in this state there is little
release of pro-inflammatory cytokines and resistance to activation by agents
such as lipopolysaccharides (LPS). In this TH2/alternative state macrophages
promote extracellullar matrix formation and angiogenesis. Duffield (2003)
suggests that one major difference between beneficial resolving inflammation
and detrimental chronic inflammation is a failure to transition between TH1 and
TH2 states of activation, leading to tissue destruction and organ failure. It is our
hypothesis that this transitional failure is a consequence of aging, predisposing
the brain to neurodegenerative disease.
Given these observations, it is possible to hypothesize that the dual glial
response, associated with dopaminergic neuron loss in SN and striatum may be
related to the balance between TH1/TH2 activation states. An increase in the
TH1 cytokine IFN is observed in PD (Liu 2006) but in mice lacking IFN
indicates that there is a protection from damage resulting from MPTP insult since
in the mice lacking IFN there was not a measurable pro inflammatory response
(Mount, Lira et al. 2007). Microglia are the immuno-competent cells of the brain.
In the early phase of the injury microglia are activated promptly along the lines of
TH2/alternative pathways, expressing numerous molecules with important
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immune function and trophic action that can lead to neuroprotection (Batchelor,
Liberatore et al. 1999). Later, their prolonged activation increases the expression
of a variety of neurotoxic factors characteristic of TH1/classical activation and, it
is at this stage that they may contribute to the degeneration of the dopaminergic
neurons. In support of this dual role there have been reports that blockade of the
early TH2 anti-inflammatory response using antisense to TNF on day 1 – 5
following a 6-OHDA induced lesion of the striatum the injury is more severe in
agreement with the early TH2/alternative activation state being neuroprotective.
This also demonstrated that blocking the late phase chronic TH1/classical
activation resulted in a smaller lesion in agreement with the chronic TH1/classical
activation phase being detrimental and a cause of ongoing DA cell death
following the 6-OHDA injury (Gemma, Catlow et al. 2007).

1.1.2 Aging and neurodegeneration
Aging is a natural process that affects physiology in many different ways,
from physical to behavioral aspects. As we age our physiological functions
decrease and we become more prone to diseases. Aging is the key ingredient
from where neurodegenerative diseases emerge. At the moment therapeutic
treatments are aimed at helping delay the onset and progression of many
neurodegenerative disorders; but no successful therapy has been yet developed
to effectively alleviate such devastating neurodegenerative diseases as PD. With
this in mind, our goal is to examine the involvement of inflammation in the aging
brain that leads to neurodegenerative disease. In this study we will look at the
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use of natural products, like antioxidants as a possible preventive method. In
both aging and neurodegeneration, the role of inflammation is critically linked to
ROS and pro inflammatory cytokines, which are known to contribute to
degenerative process that are part of the normal aging.

1.1.3 Aging and oxidation
Aging is a natural process that affects us everyday in a variety of ways
ranging from our physical appearance to our social behaviors. The process of
aging is characterized by a decrease in physiological functioning as well as an
increase in incidence of diseases that can lead to death. The free radical theory
of aging, originally proposed by Harman in 1956, (Harman 1956) states that
aging and its related diseases are a result of free radical induced damage to
important molecules and the inability of the endogenous system to maintain
homeostasis (or an adequate anti-oxidant balance). It is believed that free
radicals have deleterious effects not only in cell components and connective
tissue but also in the accumulation of reactive oxygen species (ROS), that over
time contributes to the aging process. The theory was strengthened by the
discovery in 1969 of the enzyme superoxide dismutase (SOD) (McCord and
Fridovich 1969). The existence of an intracellular enzyme whose sole function is
to remove superoxide anions (O 2 -) has provided strong biological evidence that
free radicals need to be removed quickly from the cellular compartments.
In 1972, Harman expanded his original studies to include the involvement
of mitochondria in the physiological processes of aging (Harman 1972). Harman
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proposed that mitochondria generate a significant amount of cellular energy and,
through consumption of most of the intracellular oxygen, set the limit on the
lifespan. Approximately, 90% of cellular oxygen is consumed within the
mitochondria, mainly in the inner membrane, where oxidative phosphorylation
occurs. Since that time, several studies have emerged to give support to this
theory, and the free radical theory of aging has been expanded to the
mitochondrial free radical theory of aging. The premise of the mitochondrial freeradical theory of aging is that mitochondria are both producers and targets of
reactive oxidative species. According to this free radical theory, oxidative stress
attacks mitochondria leading to increased oxidative damage. As a consequence,
damaged mitochondria progressively become less efficient, losing their functional
integrity and releasing more oxygen molecules. This leads to further oxidative
damage to the mitochondria and culminating in an accumulation of dysfunctional
mitochondria with age.
ROS are also important in maintaining homeostasis because several
studies have shown that they can act as cellular messengers. For instance,
oxidants (nitrous oxide [NO]) act as signaling molecules to promote long term
potentiation (LTP) (Knapp and Klann 2002). Moreover, it has been shown that
stimulation of growth factors induce the production of free radicals that are
subsequently involved in regulating the proliferative response (Finkel 1998).
The human organism is equipped with very efficient antioxidative defense
mechanisms, which among others, include antioxidative enzymes such as SOD,
catalase, glutathione peroxidase, and glutathione reductase (Poon, Calabrese et
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al. 2004). When the production of ROS is prolonged, the endogenous reserves
of antioxidants become insufficient, leading to cell damage. Similarly, the
production of ROS below physiological levels induces a decreased proliferative
response.
Even though mitochondria are the main source of ROS, there is a second
source known is peroxisomal B-oxidation of fatty acid which generates H 2 O 2 as a
by-product. Peroxisomes are organelles responsible for degrading fatty acid as
well as other molecules (Beckman and Ames 1998). Peroxisomes possess a
high concentration of catalase so whether or not leakage of H 2 O 2 from
peroxisomes contributes significantly to cytosolic oxidative stress under normal
circumstances is still unclear. Phagocytic cells are another important source of
oxidants; these cells defend the central nervous system against invading
microorganisms and clear the debris from damaged cells by an oxidative burst of
nitric oxide, H 2 O 2 , and O 2 -.
As we age, there is a decline in normal antioxidant defense mechanisms
which make the brain more vulnerable to deleterious effects as a result of
oxidation. Oxidative stress and inflammation is also known to be a main
contributor to diseases such as Alzheimer’s disease and Parkinson’s disease.
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1.2 Parkinson’s disease and inflammation
Inflammation in the brain, in particular, activation of microglia and dendritic
cells has been increasingly associated with the pathogenesis of PD, as well as
several other neurodegenerative disorders. Aside from the dramatic loss of
dopaminergic neurons associated with PD, it has been shown that the SN is also
the site of a robust glial reaction in PD patients and in humans with MPTP
poisoning (Langston et al., 1999) and in response to -synuclein in both humans
and animal models (Austin et al., 2006;Reynolds et al., 2007;Su et al., 2007).
Increased numbers of microglia and the presence of activated microglia have
been noted in several studies and they are present in both early and late stages
of the disease (Gao, Jiang, et al. 2002 1 /id) (Mirza et al., 2000;Banati et al.,
1998;McGeer and McGeer, 1997). Activated microglia appear to have a Janus
face in that there is upregulation of both neuroprotective and neurotoxic factors.
On the other hand, the persistent activation of microglia can lead to neuronal
death. It is postulated that manganese toxicity, which resembles PD in many
respects, is due to an activation of microglia which leads to production of nitric
oxide and thus oxidative damage to neurons (Chang and Liu, 1999). There are
two types of activation for macrophages, which applies to microglia as well.
During neurodegenerative disorders microglia is usually in the TH1
classical activation state measured by the high levels of TNFα and other proinflammatory cytokines and low levels of anti-inflammatory cytokines like IL-10.
Liu (2006) observed higher levels of TH1 cytokines in an MPTP PD model
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suggesting the involvement of microglial prolonged activation led to the DA cell
death in his model.

1.2.1 Incidence of Parkinson’s disease
Several studies have looked at the incidence of PD with respect to age,
gender and ethnicity. A study by Van Den Eeden suggested that the prevalence
of PD varies by race and ethnicity. The study found that the incidence among
ethnic groups was highest in the Hispanic culture; this was followed by nonHispanic whites, Asians, and African Americans (Van Den Eeden, Tanner et al.
2003). In another study, scientists looked into a more diverse population within
the United States using one of the most culturally diverse cities, New York City.
In this study they compared three ethnic groups: African Americans, Caucasian
and Hispanic, over a period of 4 years. It was found that the age-adjusted
prevalence for women was lower than that for men in each ethnic group.
However, within the female cohort incidence of PD was highest in the Hispanic
sector. Hispanic women had a higher incidence than African Americans and
Caucasians. When examining the male cohort, the highest rate was found to be
among African Americans. When the data was examined for gender and ethnic
groups with age as a co-factor the cumulative incidence of PD was found to be
lower for women than men in a group of 90 year old patients. The cumulative
incidence among them was found to be more prominent in African Americans
than Caucasian or Hispanic (Mayeux, Marder et al. 1995). At this time there is
no definitive study indicating the ethnic group with the highest risk for PD and
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further investigation is needed. There is strong evidence that males are more
susceptible than females and that African Americans and Hispanic ethnic group
have higher incidence than Caucasians of both genders.

1.2.2 α-synuclein
One non amyloid forming presynaptic protein that has been implicated in
the etiology of PD is a 140a.a. nuclear protein called α-synuclein. The exact
physiological function of α-synuclein is still unknown. Evidence suggests that it is
involved in many processes from DA neurotransmission, to synaptic vesicle
function and signal transduction (Gorbatyuk, Li et al. 2008). In some forms of
familial PD the α-synuclein gene is triplicated or carries a missense mutation
(A53T, A30P, or E46K). Some of the mutations reported in different families
have helped us in achieving a better understanding of the etiology of PD and the
pathological mechanisms involved.
α-Synuclein is particularly prone to misfolding and aggregating into small
oligomers and larger fibrils which form the main component of Lewy bodies.
Lewy bodies are normally intracytoplasmic structures containing aggregated αsynuclein, however, it has been shown that these structures can be also found
extra-cellularly and surrounded by activated microglia and complement system
(Yamada, McGeer et al. 1992; Zhang, Wang et al. 2005). To this day the exact
function of the Lewy body is not clear but there is evidence of its involvement in
PD pathology, through the activation of microglia. While larger aggregated fibril
structures of a-synuclein have been associated with neurotoxicity, recent
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evidence suggests that Lewy bodies may be protective since oligomeric αsynuclein is toxic and it has been found in large quantities sequestered inside
lewy bodies. It has also been suggested that α-synuclein activates microglia; this
can be seen in familial cases of PD, where mutations in the α-synuclein gene
causes it to oligomerize and form a toxic specie of α-synuclein (Uversky, Li et al.
2001). It is believed that α-synuclein must be released into the extracellular
space in order to trigger the activation of microglia. This activation causes
microglia to proliferate, respond and clear the environment. This can ultimately
lead to chronic activation of microglia. As the amount of α-synuclein released into
the extracellular space increases more pro inflammatory cytokines and ROS are
released, leading to further degeneration of not only DA neurons of the SN pars
compacta but also damaging the microenvironment where other DA neurons are
present. This could further exacerbate the progression of the PD pathology αsynuclein belongs to a family of unfolded proteins providing them flexibility to
bind to different types of proteins (Paleologou, Irvine et al. 2005). This unfolding
may facilitate the misfolding of α-synuclein in β-sheet-rich conformers
aggregating into oligomers and thus causing the progression of PD. Indeed,
recent data indicate that fibrillary α-synuclein is the major component of the Lewy
bodies and that oligomeric intermediates are the toxic species that leads to the
onset of PD (Outeiro, Putcha et al. 2008). These studies suggest that increases
in the level of expression of α-synuclein or the nucleation-dependant aggregation
of several intermediate species from monomers to fibrils are the cause of
neurodegeneration (Outeiro, Putcha et al. 2008). Furthermore, oxidative damage
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produces more aggregation which makes α-synuclein more prone to aggregate
even further leading to a neurotoxic cycle (Sherer, Betarbet et al. 2002). This
cycle is due to a decrease in glutathione (GSH), an antioxidant in charge of
removal of free radicals, in the brain. The decreased levels of GSH contribute to
the oxidative damage that occurs during DA metabolism, since it cannot protect
the brain from ROS. Brains from PD patients show evidence of apoptosis and it
is found alongside with aggregated α-synuclein, progressive oxidative damage
and increased H 2 O 2 -induced caspase dependant cell death. All of this
aggregation and decrease in protection against ROS lead to the progressive
neurotoxic cycle. While these putative mechanisms remain speculative at this
date, the data so far establishes that oligomers of α-synuclein are a critical step
for triggering neurodegeneration of the DA neurons in the SN of the PD brain.
There have been several papers establishing the existence of mutations in
endogenous α-synuclein that cause PD pathology. Using knockout mice,
researchers have found that α- synuclein is involved with regulation of
transcription factors and is associated with synaptic vesicle functions, from
determining the size of the vesicle to the release of its content (Wersinger and
Sidhu 2003). For example, investigations performed by Wersingerand and
Yavich, Tanila et al. 2004 indicates that α-synuclein may be involved in the
regulation of release and reuptake of dopamine at the synaptic cleft or synapse.
The multiple, diverse functions of α-synuclein is a significant reason why most
scientists have not been able to pinpoint a accurate function or a more specific
role of α-synuclein. A paper published by Gorbatyuk (2008) compared the
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phosphorylation states of alpha-synuclein (phosphorylated versus nonphosphorylated). He looked at wild type mice in which the serine amino acid
number 129 (Ser129) of α-synuclein was replaced with either alanine or
aspartate. The replacement of serine to aspartate was done to activate the αsynuclein protein by phosphorylation resulting in increase α-synuclein function
and alanine to keep it in a non-phosphorylated state (inactive). This study
showed that even though the mutated α-synuclein, caused the phosphorylation
and increase in α- synuclein, production it did not cause a lesion in the SN. All
the TH positive cells remained intact, therefore dopamine was present. This
indicates that the SN was not affected by increased α-synuclein expression. On
the other hand, the non-phosphorylated mutation wiped out the DA cells as
reflected by decreasing TH positive staining. It was concluded that the nonphosphorylated state was the probable cause for dopamine depletion rather than
the excessive expression of α-synuclein in the brain (Gorbatyuk, 2008).

1.3 Natural sources of anti-inflammatory agents
There is now accumulating evidence that selection of appropriate whole
foods or the addition of antioxidants into the diet is beneficial to increasing the
functional life span, if not the maximal lifespan (Casadesus, Shukitt-Hale et al.
2002). Vitamin E (Vit E) is the most studied antioxidant supplement and has
been shown to increase longevity in short lived species such as C. elegans and
the rotifer Asplanchna brightwelli (Sawada and Enesco 1984; Harrington and
Harley 1988) but there is little evidence that it increases maximum lifespan in
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rodents (Blackett and Hall 1981; Morley and Trainor 2001). The evidence for an
improvement in functional lifespan, in other words improvements in aspects of
physiology and brain health, is more numerous. For example, Vit E administered
to rodents can improve age-related impairments in LTP (Murray and Lynch 1998)
and improve cognitive behaviors (Joseph, Shukitt-Hale et al. 1998; Joseph,
Shukitt-Hale et al. 1999). Vit E has also been shown to have actions that can
prevent neurodegenerative disease in animal models and in in vitro studies. For
example, Vit E is neuroprotective in apoE deficient mice (Veinbergs, Van Uden et
al. 2001) and modifies A toxicity in cultured hippocampal neurons (Butterfield,
Koppal et al. 1999). A prevention of A toxicity in vivo has also been observed
(Yamada, Tanaka et al. 1999). In that study, Vit E prevented the onset of
behavioral deficits induced by infusions of A into the cerbroventricles. However,
the data in humans is less convincing: clinical prevention trials using Vit E have
not observed improvements in cognition in AD patients, although some
improvement in living performance was noted (Sano, Ernesto et al. 1996; Sano,
Ernesto et al. 1997). Epidemiological studies have not always shown a positive
link between increased intake of Vit E and decreased incidence of AD,
Parkinson’s disease or cerebrovascular disease (Lee, Cook et al. 2005; Lonn,
Bosch et al. 2005). Some studies have noted a correlation between dietary
intake of foods high in Vit E, such as nuts, or diets high in fruits and vegetables
and a decreased incidence of these diseases (Zhang, Hernan et al. 2002),
suggesting that perhaps whole food sources of antioxidants and other
phytochemicals may be of benefit.
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Fruits, vegetables, nuts and other whole foods, such as blue green algaes,
contain thousands of phytochemicals, including polyphenolic compounds that
express antioxidant activity and anti-inflammatory compounds (Annapurna,
Deosthale et al. 1991; Mayeux, Marder et al. 1995; Careri, Furlattini et al. 2001;
Reddy, Subhashini et al. 2003). Some of these foods, such as the blue green
algaes, also contain omega fatty acids including gamma-linolenic acid (GLA) that
can act to reduce lipid peroxidation and also reduce inflammation. Nature has
packaged a wide array of phytochemicals that likely act in synergy to promote
health. The area of nutritional neuroscience is growing quickly and there are
many studies on the effects of whole foods and herbs as neuroprotective agents.
Green tea has been widely studied; one of the polyphenolic components
of green tea is (-)-epigallocatechin-3 gallate (EGCG). EGCG has been
extensively researched for its anticarcinogenic effects (Lin and Liang 2000;
Moyers and Kumar 2004); and, it has also been shown to have actions that
inhibit pro-inflammatory cytokines (Ahmed, Rahman et al. 2002; Han 2003).
Green tea catechins and, more specifically, EGCG have been examined for
activity in Alzheimer’s disease. EGCG has been shown to reduce amyloid
precursor protein cleavage that produces A in primary neurons derived from
Swedish mutant APP-overexpressing mice. When EGCG is given to these Tg
APP sw 2576 mice, there is a reduction in amyloid load in the brain (Rezai-Zadeh,
Shytle et al. 2005). EGCG also protects against A toxicity in cell cultures, an
action that is likely related to its antioxidant activity (Levites, Amit et al. 2003).
Other phytochemicals that have been studied for potential activity in Alzheimer’s
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disease include curcumin and other related flavones as well as flavonoids, such
as quercetin (Frautschy, Hu et al. 2001; Kim, Park et al. 2005; Ringman,
Frautschy et al. 2005). Further, blueberries have also been shown to reduce
amyloid load in an animal model of AD (Joseph, Denisova et al. 2003).
Foods such as blueberries, spinach, and spirulina, a blue green algae with
high oxygen radical absorbance capacity (ORAC = 320 µmol for blueberries
13,000 µmol for spirulina; (Gemma, Mesches et al. 2002)), have also been
studied extensively for neuroprotective actions. ORAC is a method use to
measure the antioxidant capacity in this case, a natural product. In this method
molecules are tagged by a fluorescent marker, ORAC measures the oxidative
degradation of the fluorescent molecule when is heated. For example, in the
cerebellum there is a correlation between the loss of function of -adrenergic
receptors in the aged brain and a loss in the ability to learn complex motor skills
(Bickford 1993). Feeding aged F344 rats a diet rich in spinach (ORAC= 1260
µmol) improves cerebellar -adrenergic receptor function and improves motor
learning that is associated with a decrease in oxidized glutathione and the proinflammatory cytokine TNF (Bickford, Gould et al. 2000; Cartford, Gemma et al.
2002). Further studies have attempted to correlate the ability to improve
cerebellar -adrenergic receptor function with the in vitro antioxidant capacity of
the foods added into the diet. For example, cucumber (ORAC= 126 µmol) is very
low in polyphenolic compounds and, when added to the diets of aged rats, there
was no improvement in cerebellar -adrenergic receptor function and no
reduction in malondialdehyde (a marker for oxidative stress) or TNF (Gemma,
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Mesches et al. 2002). On the other hand, spirulina, a blue green algae that has a
very high ORAC value when added to the normal rat diet (0.1% w/w) significantly
improved -adrenergic receptor function, decreased malondialdehyde and
reduced pro-inflammatory cytokine levels (Gemma, Mesches et al. 2002).
Although correlations between reduced markers of oxidative stress and
inflammation do not guarantee a causative relationship, there is increasing
evidence from many studies supporting this hypothesis.

1.3.1 Natural products as therapeutic agents in Parkinson’s disease models
Blueberries and spirulina have also been shown to be neuroprotective in
animal models of Parkinson’s disease. During brain injury and
neurodegenerative disease such as PD, neuroinflammation is involved in the loss
of dopamine neuron; thus, it is hypothesized that diets enriched with antioxidants
and anti-inflammatory factors may modulate this neurodegeneration. In a study
performed by Strömberg (Stromberg, Gemma et al. 2005), diets enriched with
blueberries and spirulina were tested as a means to enhance the recovery of
striatal dopamine loss and activation of transient microglia after injury using a PD
model. The model used injections of 6-OHDA into the dorsal striatum of rats to
cause DA neuron loss. This area is known to be susceptible to injury and DA
fibers are lost in the striatum soon after lesion and this is followed by a loss of DA
neurons in the substantia nigra that begins at about 2 weeks post injury and
continues for several weeks. In this study, the investigators looked at the
inflammatory response following the 6-OHDA injection into the striatum of rats
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that were fed a diet supplemented with either blueberries (2%) or spirulina (0.1%)
into the striatum. At one week after the lesion DA degeneration was observed in
the striatum and in the globus pallidus of all the animals with the lesion. At this
time point no differences in the size of the area of DA fiber density in any of the
diet groups were noted. The levels of OX-6 positive microglia, an
immunohistochemical marker for MHC Type II complex, were also analyzed. In
the animals fed spirulina and blueberry, the numbers of OX-6 positive cells
increased significantly in both the striatum and globus pallidus. The OX-6
positive cells were located in the area where TH fibers were missing. One month
after the lesion there was a reduced size of the TH-negative zone in the
blueberry and spriulina treated rats, showing that there was significant sprouting
of the remaining TH fibers and regeneration of DA into the lesioned areas.
Furthermore, there was a lower amount of OX-6 positive staining in the striatum
of animals fed the blueberry or spriulina diet, but an increase in the stain of OX-6
positive cells in the striatum of the control animals. When it came to the globus
pallidus, there was no significant difference from the control animals that were
fed the diet and had the lesion. Strömberg concluded that reinnervation of areas
where there is a loss of DA terminals can be enhanced through the use of
antioxidants and anti-inflammatory plant- or fruit-derived chemical compounds.
Tumor necrosis factor (TNF-α) is a pro-inflamatory cytokine that, when
functioning properly it activates a casacade of signals used to assist in the
presence of an immune stimulus. In an immunocompetent system, both pro (IL1) and anti (IL-10) inflammatory responses can be seen during an immune
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response towards a stimulus. As we age, our system becomes more
immunocompromised making the brain more prone to chronic inflammatory
response rather than acute activation of cytokines. This chronic activation alters
the microenvironment making it more hostile for the CNS cells. This eventually
causes detrimental loss of neurons and cells necessary for the brain to function
properly. As in the case of PD, chronic activation makes DA cells more prone to
degeneration and eventually leads to their death.
It has been observed that, in models with PD pathology, as the number of
dopamine neurons decreases, TNF increases. It is known that TNF, is
located in the activated microglia in the substantia nigra, especially in PD
patients. Therefore, in the presence of injury, microglia can be seen in the early
and late phase of an immune response. As injury progresses, the amount of
activated microglia also increases leading to both neuroprotection and
neurotoxicity. Neurotoxicity can be seen when the immune system cannot shut
down the production of proinflammatory cytokines and other specialized
cytokines, eventually causing the deterioration of brain tissue. As stated
previously, TNF-α has a dual effect; first, neuroprotection following injury where
there is an immediate response of phagocytosis where damaged tissues and
secretion of trophic factors, is observed. Second, when the immune response
becomes chronic with a continual release of pro-inflammatory cytokines and
ROS which are detrimental to the brain. In this study, a lesion was created using
6-hydroxydopamine (6-OHDA) in dorsal striatum of rats to simulate a
parkinsonian brain. The animals were separated into two groups, one receiving
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a daily dose of antisense oligodeoxyribonucleotide to TNF on days 1 thru 7 and
the other receiving the same antisense on days 5 thru 15 after the lesion
(Gemma, Catlow et al. 2007). The day after the last injection the animals were
euthanized, their brains were then removed and processed for
immunohistochemistry. There was an increase size of the lesion as measured
by the TH negative zone (ipsilateral side) compared to the controls of the group
of animals injected from days 1 thru 7. The opposite effect was observed when
the inhibition of TNF was delayed until days 5-15 following the lesion and in
these animals a neuroprotective effect was observed in that the TH negative
zone was signficantly reduced. This indicates that the release of TNF is
protective at the beginning of injury, but that it is toxic when is induced
chronically. TNF-α decrease the survival of DA neurons, this decrease, due to
overexpression of TNF has also been noted in transgenic mice where TH cells
have decreased.

1.5 Fractalkine (CX3CL1)
Thus examining the role of inflammation in the progression of disease has
become a central theme in neurodegenerative disease research. An important
element typically present in microglia is the G- protein coupled receptor
(CX3CR1) chemokine fractalkine (CX3CL1), a ligand released by neurons that
plays a “calming” role to reduce microglial activation. Fractalkine exists in both
membrane-bound and soluble forms. Its membrane-bound form displays
adhesion properties and consists of an intracellular domain and a
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transmembrane domain. Its soluble form results from the cleavage of
membrane-bound fractalkine by the metalloproteinase ADAM 10 and ADAM 17
(Zujovic, Benavides et al. 2000). In contrast to many other chemokines,
fractalkine binds to only one receptor (CX3CR1). This receptor responds to
membrane-bound fractalkine and to the soluble form. Fractalkine acts in vitro as
an anti-inflammatory molecule by down regulating pro inflammatory cytokines
such as, IL1, TNF and IL-6 production (known as TH1 profile). Microglial
neurotoxicity is partially controlled by fractalkine as part of its anti-inflammatory
role. Fractalkine is reduced in the aged brain and this reduction may be one of
the main players in the imbalance of pro-inflammation in opposition to anti
inflammatory response of aging brain. In a study performed by Cardona (2006),
several models were used to show that CX3CR1 deficiencies dysregulate
microglial responses and can result in neurotoxicity. The three models used
were: a CX3CR1-/- mice, a model of PD and a transgenic model of amyotrophic
lateral sclerosis (ALS). Mice that lacked the CX3CR1 showed an increase in
cytokines released in response to LPS and thus increased cell death. This
model also showed increased susceptibility to MPTP in the CX3CR1-/- mice,
since there was a significant increase of TH1 classical activation state and higher
levels of TNF-α in MPTP-treated animals. In the ALS model the mice also
showed decrease neuronal survival as compared to the CXCR1+/+ control. This
illustrates the importance of microglial activation in neurotoxic processes.
In a recent paper by Wynne, (2010), they looked at how the interaction
between CX3CL1/CX3CR modulated the activation of microglia. In this study
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they injected LPS intraperitoneally to induce an immune response with the
purpose to determine the age associated impairment due to the excessive
activation of microglia in the brain when CX3CL1/CX3CR1 is decreased. They
saw that in the aged rats (18-22mo) the levels of CX3CL1 were reduced and that
CX3CR1 was decreased with LPS injection and IL1 was seen increased after 4
hours as compared to the controls which remained unchanged. They also noted
there was a decrease in expression of TGFβ in the aged group. In another study
Cx3CL1 was also seen at reduced levels in the aged group but when it was
treated with Cx3CL1 this attenuated the increase in active microglia. This study
also points out that the use of CX3CL1 activates phospatidylinositol-3 kinase
pathway maintaining microglia in a quiescent state (Lyons, Lynch et al. 2009).

1.5.1 Fractalkine, aging, and neurodegeneration:
Aging is a primary risk factor for neurodegenerative disease, thus it
becomes important to understand what changes in the aged brain to make the
environment permissive to degeneration. One primary change is in the innate
immune system observed by a shift in the activation state of microglia. Many
papers have indicated an increased number of microglia in early and late stages
of PD. The dual role of microglia has shown that they may be beneficial in the
early stages of disease progression or in response to acute injury because
microglia phagocytose damaged tissues and secrete trophic factors thus
preventing deterioration of neurons. On the other hand, the extended action of
microglia after the affected area has been cleared, can be neurotoxic. Microglia
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play an important role in the brain as the resident immune cells that under normal
conditions play a role in immuno surveillance. Microglia becomes activated when
minor disturbances enter the brain through injury, head trauma or any
immunological challenge (Gao, Jiang et al. 2002; Zhang, Wang et al. 2005).
Once microglia cells are activated they express a series of cytokines and change
to a macrophage-like phenotype. These cytokines allow for microglia migration to
the site of injury and expression of different cell surface markers.
It has been shown that lipopolysaccharide (LPS) injections induces
microglial activation in rat neuronal-glial cultures. This activation led to the
production of neurotoxic factors such as NADPH which in part released ROS
species and led to neuronal damage in the SN (Gao, 2002). The release of
superoxide is consistent with the idea that dopaminergic neurons are very
susceptible to this type of insult (Zhang, 2005). Once microglia becomes
activated they proliferate, acquire a macrophage-like phenotype, and increase
expression of different cell surface markers and release cytokines.
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CHAPTER 2

MATERIALS AND METHODS

2.1 Animals
All experiments were conducted in accordance with the National Institute
of Health Guide and Use of Laboratory Animals. All protocols and procedures
were approved by the Institutional Animal Care and Use committee of the
University of South Florida, College of Medicine. 3 month old male Fisher 344
(F344) rats (Harlan Sprague Dawley, Indianapolis, IN), were pair-housed in
environmentally controlled conditions (12:12 h light:dark cycle at 21±1°C) and
provided food and water ad libitum. Animals were excluded from the study if they
developed post-surgery infection, the osmotic pump or cannula was dislodged, or
placement of the cannula was not at specified coordinates on post-mortem
evaluation.
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2.2 Surgical Procedures

2.2.1 AAV9-α-synuclein or AAV9-GFP
Male Fischer 344 rats (Harlan Labs, Indianapolis, IN) are fed either an
NIH-31 control diet (Harlan Tek 0365) or 0.1% a Spirulina enriched diet,
5mg/day, (Earthrise taluma, CA) for a period of 30 days starting from day zero.
We received the adeno-associated virus vectors (AAV9) with green fluorescent
protein (GFP) and AAV9 with α Syn, as gifts from Dr. Ronald Klein. On day 31
surgeries were performed delivering AAV-9-GFP, AAV9-α Syn, and vehicle.. The
solution was diluted to 2.1x1012 vg/ml with lactated ringer’s solution, as a vehicle
and was frozen at (-80°C) until surgery date.
Stereotaxic surgeries were performed for the delivery of this vector. After
rats were anesthetized with 3-5% isoflurane, stereotaxis surgery was performed
using the following coordinates from Bregma: AP= -5.3, ML= +2.1 and DV= -6.3
from the brain surface. A small hole was drilled in the skull for access to the
brain, and treatments were administered using a microsyringe pump.
Approximately 2ul of the treatment or vehicle was delivered with a 25ul syringe
and a 26 gauge blunt tip needle at a rate of 1ul per minute. The syringe was left
in place for 2 minutes after the infusion to make sure the vector was delivered
and to limit the backflow of the solution up the needle track. Then the syringe
was removed slowly and the incisions were closed.
After a 2 week incubation period for each group (2 weeks, 1 month, and 4
month) animals were anesthetized with nembutal (50 mg/kg, i.p.) and perfused
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transcardially with phosphate buffered saline (PBS) followed by 4%
paraformaldehyde. Brains were removed and postfixed in paraformaldehyde
overnight; and then transferred to a 30% sucrose/PBS solution for at least 16
hours. Coronal cryostat sections were cut (40 μm) using a cryostat, collected,
and stored in a cryoprotectant solution at –20°C until processing.

2.2.2 6-OHDA and fractalkine
All surgical procedures, followed previously described methods (Gemma,
Catlow et al. 2007; Bachstetter, Morganti et al. 2009). Rats were anaesthetized
with isofluorane. Depth of anesthesia was monitored and adjusted as necessary.
All procedures were performed using sterile techniques. Briefly, the head was
incised using a sterile scalpel blade; bleeding was minimized using cotton swabs.
A hole was drilled for placement of a skull screw to be used as anchors for dental
acrylic. A second hole was drilled over the dorsal striatum for placement of a
cannula at the following coordinates: AP=+1.0; ML= +3.0 and V= -4.5. 6-OHDA
(20µg/4µL) was infused at a rate of 0.5µL per minute into the left striatum
(Gemma et al., 2007). Immediately after the 6-OHDA lesion a stereotaxically
implanted cannula (coordinates: AP=+1.0; ML= +3.0 and V= -4.5) was affixed to
the skull by dental acrylic and attached to an osmotic minipump inserted
subcutaneously, for a sustained delivery of saline for 7 days. After the first 7
days, a mid-scapular incision was made and the saline pump was switched for
the treatment pump to deliver 3ng/day (n=5), 30ng/day (n=4), or 90ng/day (n=5)
of FKN or 90ng/day of heat-inactivated fractalkine (n=6) (as a control) for 28 days
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into the site of the lesion (Alzet model 2004: pumping rate 0.25 μl/hr (± 0.05
μl/hr); total volume 1.0mL) as previously described (Bachstetter, Morganti et al.
2009). After day 28 the rats were anesthetized and perfused transcardially with
phosphate buffered saline (PBS) followed by 4% paraformaldehyde. Brains were
then removed and postfixed in paraformaldehyde overnight; they were then
transferred to a 30% sucrose/PBS solution for at least 16 hours. Coronal
sections were cut (40 μm) using a cryostat and the sections were collected and
stored in a cryoprotectant solution at –20°C until processing.

2.3 Immunohistochemistry

2.3.1 TH Immunohistochemistry
A series of one in six sections was selected that included the anatomical
region of interest (from striatum to SN) with a random start section for each
subject for this staining. Also 1 in 3 sections were stained for the cavalieri
stereology method of volume analysis
On day one, the tissue was transfered from cryoprotectant to 0.1MPBS
(pH 7.2-7.5) and washed three times for 10 minutes each on a shaker at room
temperature (RT). Then the tissue was incubated in sodium periodate
(TBS/NaIO4) for 20 minutes at RT (60 rpm). Washed 3 times in 0.1M PBS for 10
minutes each at RT on a shaker and blocked with a PBS-Triton-serum (Normal
Horse serum; Lampire Biological Labs- cat # 7333400) for 60 minutes at RT.
After 1 hour, tissue was incubated with the primary antibody (mouse anti TH,
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1:10,000 and 1:1000 for STR; Immunostar cat# 22941) overnight at 4◦C. On day
2 of this protocol, tissue was washed 3 times with PBS and serum for 10 min
each at RT and then Incubate with secondary antibody (Horse anti mouse1:1000 from Vector cat # BA-2001) for an hour at RT. Then washed again 3
times as previously stated. The tissue is then incubated with ABC solution
(Vector Cat# PK-6100) for 1 hour at RT. and washed with PBS 3 times, then
incubated with DAB without metal enhancer (Vector Cat# SK-4100) for 2
minutes, washed and mounted on slides, after dehydration the slides are
coversliped.

2.3.2 OX-6 immunohistochemistry
One out of six sections was selected for this staining and one in every
third section was stained including beginning to end of the striatum. After
transferring the tissue from cryoprotectant wash with 0.1M PBS. Incubate the
tissue in 40% Methanol/ peroxide (MeOH) solution for 20 minutes at RT then,
wash as previously stated. The tissue was then blocked with a PBS-Tritonserum (Normal Horse serum; Lampire Biological Labs- cat # 7333400) for 60
minutes at RT. Incubated with primary antibody (Mouse anti-RT1B- 1:750 BD
cat# 554926) overnight at 4◦C. On day 2 of this protocol, tissue was wash 3
times with a solution of PBS and serum for 10 min each at RT and Incubated with
secondary antibody (Horse anti mouse with a dilution of 1:300 from Vector cat #
BA-2001) for an hour at RT. Then wash again 3 times as previously stated.
Tissue was incubated with ABC solution (Vector Cat# PK-6100) for 1 hour at RT.
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Wash again with PBS 3 times. Incubated with DAB with metal enhancer (Vector
Cat# SK-4100) for 2 minutes, washed again and mounted slides, dehydrated
tissue, and coversliped.

2.3.3 Alpha-synuclein immunohistochemistry
Only the tissue injected with AAV9-α Synuclein was stained for this step.
One in sixth sections were selected. On day 1 tissue was transferred from
cryoprotectant in to a wash with 0.1M PBS for 3 times at RT. Tissue was
incubated in a 0.1%H2O2 solution for 10 minutes at RT, and then washed. The
tissue was then blocked with a PBS-Triton-serum (Normal Horse serum; Lampire
Biological Labs- cat # 7333400) for 60 minutes at RT and incubated with primary
antibody (mouse anti α Synuclein 1:1000; Zymed cat # 18-0215) overnight at
4◦C. On day 2, of this protocol, the tissue was washed 3 times with a solution of
PBS and serum for 10 min each at RT, incubated with secondary antibody
(Horse anti mouse- 1:1000 from Vector cat # BA-2001) for an hour at RT. Then
washed again 3 times as previously stated and incubated with ABC solution
(Vector Cat# PK-6100) for 1 hour at RT. Sections were washed again with PBS
3 times and incubated with DAB without metal enhancer (Vector Cat# SK-4100)
for 5 minutes, wash again and mount slides, dehydrate tissue and coverslip.

2.3.4 NeuN immunohistochemistry
Using one in sixth sections, tissue were transferred from cryoprotectant
into 0.1M PBS and incubated in 40% methanol/2% H2O2 solution for 15 minutes
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at RT; washed with PBS for 3 times at RT. Blocked the tissue with a PBS-Tritonserum (Normal Horse serum; Lampire Biological Labs- cat # 7333400) for 60
minutes at RT and then incubate with primary antibody (Mouse anti NeuN
1:1000; Millipore Cat# 3777) overnight at 4◦C. On day 2, of this protocol, wash 3
times with a solution of PBS and serum for 10 min each at RT. Incubate with
secondary antibody (Horse anti mouse- 1:300 from Vector cat # BA-2001) for an
hour at RT. Then wash again 3 times as previously stated. Incubated with ABC
solution (Vector Cat# PK-6100) for 1 hour at RT. Washed again with PBS 3
times. Incubate with DAB without metal enhancer (Vector Cat# SK-4100) for 2
minutes, wash again and mount slides, dehydrate tissue and coverslip.

2.3.5 GFP immunohistochemistry:
Using one in sixth sections, tissue were transferred from cryoprotectant
into 0.1M PBS and incubated in 40% methanol/2% H2O2 solution for 10 minutes
at RT; washed with PBS for 3 times at RT. Blocked the tissue with a PBS-Tritonserum (Normal Goat serum; Lampire Biological Labs- cat # 7332500) for 60
minutes at RT and then incubate with primary antibody (Chicken anti GFP
1:10,000; abcam Cat# ab13970) overnight at 4◦C. On day 2, of this protocol,
wash 3 times with a solution of PBS and serum for 10 min each at RT. Incubate
with secondary antibody (Goat anti chicken- 1:1000 from Vector cat # BA-9010)
for an hour at RT. Then wash again 3 times as previously stated. Incubated with
ABC solution (Vector Cat# PK-6100) for 1 hour at RT. Washed again with PBS 3
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times. Incubate with DAB without metal enhancer (Vector Cat# SK-4100) for 1
minute, wash again and mount slides, dehydrate tissue and coverslip.

2.4 Stereology
Stereological methods were used for quantification of cells present in the
tissue stained. The tissue was viewed with an Olympus BX60 microscope and
MBF CX 9000 camera. The tissue was quantified using optical fractionator from
MBF software of Stereo Investigator (Ver.8). TH positive cells were quantified
within the area of the SN pars compacta. The sampling site was customized to
count 300 cells per brain. For counting TH positive cells the counting frame (CF)
was 70 x 70 with a virtual counting grid (CG) of 140 x 140. For OX-6 cells CF
was 400 x 300 and CG of 400 x 300. For NeuN staining CF was 75 x 75 and CG
is 160 x 160. For counting the locus coerulus (LC) the CF was 125 x 125 and
CG 160 x 160. For GFP staining CF was 125 x 125 and CG 160 x 160. The
estimated volume (μm3) of TH negative zones in the striatum (STR) was
quantified using cavalieri method of unbiased stereology of every third section.
Also, the expression of OX-6 positive cells was quantified in the STR through the
use of cavalieri. Both staining were quantified using a grid spacing of 200μm
using a 2x/0.06 objective.
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2.5 Tissue processing:
Tissue from the striatum was homogenized using an electric tissue
homogenizer in 1:10 weight to volume ratio of ice-cold RIPA buffer (Millipore;
Billerica MA) containing protease inhibitors and EDTA (Pierce; Rockford IL).
Following homogenization, sample lysates were centrifuged at 10,000 x g at 4ºC
for 15 minutes, the cleared supernatant was collected.

2.6 Western Blot
BCA protein assay (Pierce) was used to determine the total protein
concentration for each fraction sample. 50 µg of total protein per lane was
loaded onto a 4-15%, 10% SDS-polyacrylamide gel (BioRad; Hercules CA), or 415% non-denaturing polyacrilamide gel (Bio-Rad; Hercules, CA)for
electrophoresis. Proteins were transferred onto a nitrocellulose membrane for
immunodetection. The membrane was blocked for 1-hour in 5% non-fat dry milk
(NFDM) in PBS-tween (PBS-T, 0.1%). Antibodies for mouse alpha synuclein
(Invitrogen; Camarillo, CA 1:1000), mouse beta-actin (Sigma; 1:3000), (CX3CR1
Abcam Cambridge, MA, 1:1000), were incubated overnight at 4oC in 1% NFDM
in PBS-T. Following washes, anti-rabbit and anti-mouse secondary antibodies
(LiCor; Lincoln NE 1:5000) were incubated for 1-hour at room temperature in 1%
NFDM in PBS-T. Membranes were scanned using LiCor Odyssey Imager and
raw intensity for each band was measured using LiCor Odyssey image analysis
software.
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2.7 Statistical Analysis
Two way ANOVA was be performed after stereology to determined
significance between insult times the treatment (insult x treatment). Also, unpair
t-test to assess whether the means of two groups are statistically different from
each other using 95% confidence interval. One way ANOVA was also performed
looking at the comparison between the groups with 95% CI. Statistical analysis
was done using GraphPad Prism 5. A minimum sample size of 6 for
immunohistochemistry and biochemistry were sufficient for measurement and
analysis of data collected. Two additional rats were used in case of any
problems that may occur.
Data was presented as mean cell number ± SEM averaged across
subjects per group, or mean volume ± SEM averaged across subjects.
Statistical comparison of the data was performed using GraphPad Prism version
5.00 for Windows (GraphPad Software, San Diego California USA,
www.graphpad.com). Group interaction was analyzed with one-way ANOVA,
followed by Tukey post-hoc analysis.
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CHAPTER 3

INVESTIGATION OF NEURONAL EFFECTS OF ADENO ASSOCIATED VIRAL
VECTOR 9 USING HUMAN WILDTYPE α- SYNUCLEIN TO MODEL
PARKINSON’S DISEASE

3.1 Why AAV9-αsynuclein as a model for PD
The purpose of this model is to establish a viable PD model using the
adeno associated viral vector serotype 9 (rAAV9) to overexpress α-synuclein into
the SN. The use of AAV9 as a preference for this study is due to the fact that
serotype 9 has efficient transduction level after a single use compare to other
serotypes (Klein, Dayton et al. 2008). Serotype 9 is also known to be specific for
neurons even though, is not site specific. With the use of this vector we can
efficiently deliver human wild type α-synuclein into the SN of 3 month old male
rats and successfully create a PD model.

3.1.1 α-synuclein and PD
In a recent in vivo study a group of scientists tried to demonstrate the
toxicity of the presynaptic protein α-synuclein. They suggest that during the
transitional process from monomers to aggregated oligomers is when α-synuclein
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becomes toxic. Interestingly, in their model of PD they noticed that the mutant
forms (E57K and E35K) which are known to form oligomers directly of αsynuclein were more toxic than when it formed fibrils at a slower rate. With these
results they concluded that oligomers are more toxic and they might potentially
interact with membranes by disrupting them (Winner, Jappelli et al. 2011). The
main function of α-synuclein is not entirely understood; it is involved in many
processes, such as synaptic vessel release, synaptic plasticity, vesicle formation,
genes involved with DA release, and other important functions, within and in the
surroundings of the cell. It is also known to be up regulated when there is a
presynaptic stimulus especially during the synaptic rearrangement period for
vesicle trafficking for DA release. The aggregation of α-synuclein in cells is the
biomarker for lewy body neurodegeneration. Lewy bodies are also characteristic
pathological markers of PD. They are sac like structures filled with aggregated αsynuclein. It is unclear if Lewy bodies are neuroprotective because it
encapsulates α-synuclein fibrils or adds to the neurodegeneration, but both
situations are being studies presently.

3.2 Specific material and methods

3.2.1 Surgeries with GFP/α-synuclein AAV9
Male Fischer 344 rats (Harlan Labs, Indianapolis, IN) were fed NIH-31
control diet (Harlan Tek 0365) for a period of 30 days starting from day zero. On
day 31 surgeries were performed delivering AAV-9-GFP, AAV9-α Syn, and
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vehicle. We received the adeno-associated virus vectors (AAV9) with green
fluorescent protein (GFP) and AAV9 with α Syn, as gifts from Dr. Ronald Klein.
The solution was diluted to 2.1x1012 vg/ml with lactated ringer’s solution,
which was the vehicle used as the control group. Stereotaxic surgeries were
performed for the delivery of this vector. Rats were anesthetized with 3-5%
isoflurane. Following coordinates from Bregma: AP= -5.3, ML= +2.1 and DV= 6.3 from the brain surface. Using microsyringe pump equipment 2ul of the
treatment or vehicle was delivered with a 25ul syringe and a 26ga. blunt tip
needle at a rate of 1ul per minute. The syringe was left in place for 2 minutes
after the infusion to make sure the vector was delivered. Then the syringe was
removed slowly and the incision was closed.
The day after the incubation period expired for each group (2 weeks, 1
month an 4 months) animals were anesthetized with nembutal (50 mg/kg, i.p.)
and perfused transcardially with phosphate buffered saline (PBS) followed by 4%
paraformaldehyde. Brains were removed and postfixed in paraformaldehyde
overnight; they were transferred to a 30% sucrose/PBS solution for at least 16
hours. Coronal cryostat sections were cut (40 μm) using a cryostat, collected,
and stored in a cryoprotectant solution at –20° until processing.

3.2.2 TH Immunostaining
One in sixth sections were selected that included the anatomical region of
interest (from striatum to SN) for this staining. On day one of the staining
protocol the tissue was, transfered from cryoprotectant to 0.1MPBS (pH 7.2-7.5).
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The tissue was washed three times for 10 minutes on a shaker plate at room
temperature (RT). Then incubated in sodium periodate (TBS/NaIO4) for 20
minutes at RT (60 rpm). Wash the tissue 3 times in 0.1M PBS for 10 minutes
each at RT on a shaker. Block the tissue with a PBS-Triton-serum (Normal Horse
serum; Lampire Biological Labs- cat # 7333400) for 60 minutes at RT. After 1
hour, incubate with the primary antibody (mouse anti TH, 1:10,000) overnight at
4◦C. On day 2 of this protocol, wash 3 times with a solution of PBS and serum
for 10 min each at RT. Incubate with secondary antibody (Horse anti mouse1:1000 from Vector cat # BA-2001) for an hour at RT. Then wash again 3 times
as previously stated. Incubate with ABC solution (Vector Cat# PK-6100) for 1
hour at RT. Wash again with PBS 3 times. Incubate with DAB without metal
enhancer (Vector Cat# SK-4100) for 2 minutes, wash again and mount slides,
dehydrate tissue and coverslip.

3.2.3 NeuN immunohistochemistry.
Using one in sixth sections, tissue was transferred from cryoprotectant into
0.1M PBS. Incubate in 40% methanol/2% H2O2 solution for 15 minutes at RT.
Wash with PBS for 3 times at RT. Block the tissue with a PBS-Triton-serum
(Normal Horse serum; Lampire Biological Labs- cat # 7333400) for 60 minutes at
RT. Then incubate with Primary antibody (Mouse anti NeuN 1:1000; Millipore
Cat# 3777) overnight at 4◦C. On day 2, of this protocol, wash 3 times with a
solution of PBS and serum for 10 min each at RT. Incubate with secondary
antibody (Horse anti mouse- 1:300 from Vector cat # BA-2001) for an hour at RT.
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Then wash again 3 times as previously stated. Incubate with ABC solution
(Vector Cat# PK-6100) for 1 hour at RT. Wash again with PBS 3 times.
Incubate with DAB without metal enhancer (Vector Cat# SK-4100) for 2 minutes,
wash again and mount slides, dehydrate tissue and coverslip.

3.3 Results

3.3.1 Positive transduction efficiency with AAV9-GFP as control.
We first developed a functional model of PD in which we could
demonstrate a progressive lesion of the nigrostriatal DA neurons that
recapitulated crucial events observed in PD patients with the use of an adeno
associated viral vertor (AAV9). To that end, we induced exogenous CNS
expression of α-synuclein via stereotaxic delivery to the SN of F344 rats of rAAV9 α-synuclein, using rAAV9-GFP as a virus control and Ringer’s solution as
vehicle control. In fig 3.1 we can see that rAAV9-GFP is expressed in the SN
and is only expressed in neurons.
Positive GFP was transduced using AAV 9 into the SN of rats. This
indicates that the selected AAV9 is very efficient in transferring genes of interest
to a broad range of mammalian cell types. Moreover it has limited pathogenicity,
is highly stable, and it has a long term expression after a single application.
Serotype 9 has been found to have preferences for neurons.
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AAV9 GFP+ NIH-31 diet

AAV9 GFP+ Spirulina diet

Fig 3.1
Fluorescence photomicrographs showing transduction efficiency when using the
Adeno-associated viral vector -9 (AAV-9). Panels show transduction efficiency
using a GFP reporter. Rats that received the AAV-9 GFP vector and the NIH-31
diet (A) are positive within the substantia nigra (SN), and more importantly the
pars compacta (PC) (B). Rats that received the spirulina diet also had similar
levels of expression of GFP within the SN (C) as well as in the PC (D).
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3.3.2 Transduction efficiency of rAAV9- α-synuclein
AAV9 also transduced α-synuclein efficiently into the SN as seen in figure
3.2 following the same effect seen with AAV9-GFP. α-synuclein staining can be
seen clearly in the cytoplasm of the cell bodies in the SN of these rats. αsynuclein -140 aa is a presynaptic nuclear protein associated with synaptic
vesicle and might regulate the synaptic pool, DA release and reuptake
(Gorbatyuk,2008). Also it can modulate the expression of genes involved in DA
release and can affect enzymes that had to do with chromatin remodeling and
signal transduction. It is also non-amyloid forming oligomers that eventually form
fibrils. In this micrograph we can see the α-synuclein widely express throughout
the entire SN of rats. This also confirms the fact that α-synuclein is indeed
involved in all of these functions that have to do with the release, reuptake of DA
vesicles and many other processes. Clearly α-synuclein is very noticeable in the
SN in this PD model
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Fig 3.2
Photomicrograph showing α-synuclein staining in the SN of rats. Positive
transduction can clearly be seen with the use of AAV9 transducing α-synuclein
into the SN. α-synuclein is surrounding the area were the DA cell bodies are
located within the SN of the brain.
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3.3.3 Effects of rAAV9 α-synuclein with TH positive staining
We were interested in looking at how the AAV9 α-synuclein affects the DA
neuron found in the SN of these rats following the pathology seen in PD. We
injected rats and waited two weeks, one month and 4 months and then we
sacrificed the rats. We did this since PD is a progressive neurodegenerative
disease we were interested in looking at the progression with this model from the
earlier stages. We noticed that there was no significance loss in TH positive cells
between the groups after two weeks of incubation (Fig 3.3 A). Perhaps this is
due to the fact that PD takes a while to develop and there has to be a loss
greater than 30% of the DA neurons in order to cause any significant change.
We then looked at the progression of the disease after one month and we saw
significant cell loss in the group that received the rAAV9- α-synuclein (Fig. 3.3 B).
After looking at the loss with the one month incubation group we looked at 4
month and we saw a significant decrease in the groups that received the rAAV9α-synuclein as compared to the other control groups (Fig 3.3 C). Even though
this loss after 4 month correlates to the loss of one month its not significant in its
progression.
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Fig 3 3 A-C
As determined by unbiased stereological cell counting technique, TH+ cells in the
substantia nigra pars compacta were counted and no significance was seen at 2
weeks of this study in TH+ cells in the AAV-9 alpha synuclein group as compared
to the other two groups (A). TH positive staining also had significance after 1
month of incubation with rAAV9- α-synuclein (B). Quantification of TH positive
cells after 4 month shows significance (C). Asterisk denotes significance
(P<0.05).
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3.3.4 Effects of rAAV9 α-synuclein after one month of incubation
After looking at this 2 week group we decided to inject the rats with AAV9GFP or AAV9 α-synuclein and wait a month. After a month we stained and
visualize the lesion side and we noticed that there was a deficit in the DA cell in
the SN when compared to the contralateral side (Fig 3.4). After this TH positive
cells were counted using ubiased stereological techniques. There was a
significant loss of TH positive cells in the SN pars compacta of rAAV9-αsynuclein
group compared with the control rats injected with ringers or rAAV9-GFP (Fig 3.5
A). This indicated that the α-synuclein indeed had an effect in the SNpc. Also
we quantified NeuN positive cells in the SN to confirm the loss of TH positive was
not due to inactivation of the cells or neurogenesis. We could confirm that there
is a relationship between the loss of TH positive staining and the loss of NeuN
positive cells (Fig.3.5 B).
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Fig. 3.4
Photomicrograph depicting the SN. Comparison of the significant loss that can
be seen in the SN of rats that were injected with α-synuclein after one month of
incubation (A) as compared to the contralateral side (B).
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3.3.5 Effects of rAAV9 α-synuclein on NeuN positive cells staining.
Also we perform NeuN positive staining to confirm that there is a
correlation between the loss of TH and NeuN positive staining and is not just an
inactivation of the DA cells. NeuN staining also did not have any significance
between the groups which confirms the correlation between TH and NeuN
stainings (Fig 3.5 A).
Since PD is a progressive neurodegenerative disorder we decided to also
look at 1 and 4 month after insult and see if the loss of NeuN positive cells was
larger than previously seen as compared to the other timelines. Below we can
see that there was a significant decrease in the SN when AAV9-α-synuclein was
injected as compared to the AAV9-GFP control after one month (Fig 3.5 B). We
can see the same effect with NeuN positive staining in the SN after 4 months of
incubation (Fig 3.5 C) confirming the actual loss of TH positive cells in the SN
once again after 4 months and also shows a relationship between the losses of
the two types of staining. We also compared the effects AAV9-α-synuclein had
between one month and 4 months but we did not saw a significant effect
between those two timelines. This indicates that perhaps the loss of TH positive
cells and NeuN in the two timelines was not was not sufficient to continue its
progression further. With this data we did see about a 30% cell loss in the SN
which also tells us that in order to see a progression the rats would have to be
incubated longer to get about an 60% cell loss. In another words in 4 months
there isn’t much of a progression for this model, but there is a trend for continual
loss with longer period of time.
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Fig 3.5 A-C
Quantification indicating the loss of NeuN positive cells in the SN after 2 weeks
(Fig 3.5 A), after 1 month (Fig. 3.5 B) and after 4 months (Fig 3.5C). Graphs
show the loss of NeuN positive cells when AAV9-aSYN was injected as
compared to the other groups after 1 and 4 months. There is also a correlation
between the loss of TH and loss of NeuN positive staining. Asterisk denotes
significance (P<0.05).
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3.3.6 Ipsilateral versus contralateral lesion
When the ipsilateral side was compared with the contralateral side there
was a significant difference in the rAAV9-synuclein group versus the ringers
(control) and rAAV9-GFP. In the rAAV9- α-synuclein group there was a
significantly decreased loss of TH positive cells in the SN, indicating that we
produced a viable lesion of the SN in this model of PD (Fig 3. 6). We did this
comparison since the contralateral side was not treated with α-synuclein this
serves as a wildtype control for our study. Once the loss was confirmed we
could use this model for further understanding of the progression and factors
involved in PD. Also with this we can use as a control of the loss with the rAAV9α-synuclein, since there may be fluctuation in the amount of TH present per rat at
different times in their life.
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Comparison of contralateral side versus the ipsilateral side. Significant
difference can be seen in the AAV9- α-synuclein when compared to the control
group. No significant effect was seen in the AAV9-GFP group. Asterisk denotes
significance (P<0.05).
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3.3.7 TH immunohistochemistry in the locus coerulus.
There are several papers that describe the cross communication between
the locus ceruleus (LC) and the SN. For this reason we decided to look at the
TH positive staining in the LC to see if α-synuclein had an effect that correlated
with our previous studies by decreasing TH positive cells in that area as well.
We notice that there was no significant effect in any of the groups when we
looked at the LC (Fig 3.7). Therefore the LC after 4 months of incubation was
not affected. This may be that it needed a longer incubation time to see an
effect or that the location of the two is further away to cause a lesion with this
type of model for PD.
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Fig 3.7
Quantification of TH immunohistochemistry in the Locus Coerulus. Graph show
that after four months of incubations no significant effect occurred in the LC after
α-synuclein insult.
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3.4 Conclusion
After performing this study described in this chapter we were confident in
the model system using AAV9 to overexpress α-synuclein as a model of PD. We
observed positive transduction of α-synuclein and GFP with the use of AAV9 as
the vector. Indicating that this vector performed exactly as we expected. This
vector made possible the PD model and it made it more viable since it created a
partial cell loss as seen in the early stages of PD in the human cases. Our model
of PD showed a prolonged effect after 1 and 4 months of incubation with the
NeuN positive staining also indicating that the loss of TH positive cells was an
actual loss of cells and not inactivation of the TH expression or different
fluctuation levels in the amount of TH present in a rat at that time.
On the other hand, we did not see an effect after 2 weeks of incubation.
This may be due to the fact that the progression of the lesion was seen more
prominent when the cell loss becomes to be closer to 30% at the beginning
stages. The fact that our model works for a partial loss of DA cells makes it more
valuable since it gives room to study more things involved with PD not just the
decrease in TH positive cells. Since there are many factors involved in PD
disease that contribute to the deterioration of cells and eventually leading to
pathological effects and not just one factor is no easy to determine the actual
source of this progressive disorder.
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CHAPTER 4

IMMUNOLOGICAL EFFECTS SEEN IN AAV9- α SYNUCLEIN:
DOES SPIRULINA SHOW A PROTECTIVE EFFECT IN THIS MODEL THAT IS
CORRELATED WITH ALTERED INNATE IMMUNE RESPONSE?

4.1 Immune response
In the present study, we used a PD model involving an AAV9 encoding
wild type human α-synuclein, as mentioned in the previous chapter, to induce
loss of DA neurons in the SN. It is our hypothesis that inflammation via microglial
activation may play a role in the ongoing degeneration of DA neurons following
-synuclein.

4.1.1. Effects of an antioxidant and anti-inflammatory natural product.
Spirulina, blue - green algae, has been shown to have anti-oxidant and
anti-inflammatory properties. For example it has been shown that when rats
were fed for 4 weeks with a spirulina enriched diet there was a significant
increase in regeneration of DA terminals into the TH-negative zone of the
striatum one month following an intrastriatal injection of 6-OHDA, and such
decrease was accompanied by a decrease in microglia activation as determined
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by immunohistochemical MHCII expression (OX-6), suggesting that decreases in
microglia activation modulate the beneficial effects of spirulina on 6-OHDAinduced striatal dopaminergic lesion (Strömberg et al., 2005). In the present
study we look at the effect of spirulina enriched diet on AAV-9 α synuclein
induced loss of dopaminergic neurons in the substantia nigra . The results
demonstrated that the spirulina diet attenuated the loss of dopaminergic neurons
when compared to the contralateral side. Furthermore, there was an increase in
microglia activation in AAV-9 a synuclein group which was partially reversed by
the spirulina diet. An important key ingredient seen in spirulina is phycocyanin
which is the anti-inflammatory property found in spirulina.

4.1.2 α-synuclein and inflammation.
Many papers have looked at the effects of α-synuclein in vitro and seen an
effect on microglial cells, because of this there is a believe that α-synuclein
activates microglia. Also the fact that it is known that α-synuclein can form
oligomers and these are the cause of aggregated monomers and monomers are
highly toxic, therefore, we can see that there is a relationship between the
activation of microglia and α-synuclein. Even though we are not sure how αsynuclein activates microglia. For this reason we were very curious to see the
effect α-synuclein had in our PD model in relevance to microglial activation.
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4.2 Specific Material and Methods

4.2.1 Animals:
The rats form chapter 3 were used as a control and the surgeries for this
part of the study were done alongside whit and extra set of rats receiving the
same insult, same timeline but fed a diet enhanced with spirulina.
4.2.2 OX-6 immunohistochemistry.
One out of 6 was selected for this staining and one in every third section
was stained including beginning to end of the striatum. After transferring the
tissue from cryoprotectant wash with 0.1M PBS. Incubate the tissue in 40%
Methanol/ peroxide (MeOH) solution for 20 minutes at RT then, wash as
previously stated. Block the tissue with a PBS-Triton-serum (Normal Horse
serum; Lampire Biological Labs- cat # 7333400) for 60 minutes at RT. Incubate
with primary antibody (Mouse anti-RT1B- 1:750 BD cat# 554926) overnight at
4◦C. On day 2 of this protocol, wash 3 times with a solution of PBS and serum
for 10 min each at RT. Incubate with secondary antibody (Horse anti mouse with
a dilution of 1:300 from Vector cat # BA-2001) for an hour at RT. Then wash
again 3 times as previously stated. Incubate with ABC solution (Vector Cat# PK6100) for 1 hour at RT. Wash again with PBS 3 times. Incubate with DAB with
metal enhancer (Vector Cat# SK-4100) for 2 minutes, wash again and mount
slides, dehydrate tissue, and coverslip.
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4.2.3 Tissue processing:
Tissue from the striatum was homogenized using an electric tissue
homogenizer in 1:10 weight to volume ratio of ice-cold RIPA buffer (Millipore;
Billerica MA) containing protease inhibitors and EDTA (Pierce; Rockford IL).
Following homogenization, sample lysates were centrifuged at 10,000 x g at 4ºC
for 15 minutes, the cleared supernatant was collected.

4.2.4 Western Blot
BCA protein assay (Pierce) was used to determine the total protein
concentration for each fraction sample. 50 µg of total protein per lane was
loaded onto a 4-15% (BioRad; Hercules CA), for electrophoresis. Proteins were
transferred onto a nitrocellulose membrane for immunodetection. The membrane
was blocked for 1-hour in 5% non-fat dry milk (NFDM) in PBS-tween (PBS-T,
0.1%). Antibodies for mouse beta-actin (Sigma; 1:3000), and antibody for
CX3CR1 (CX3CR1 Abcam Cambridge, MA, 1:1000), were incubated overnight at
4oC in 1% NFDM in PBS-T. Following washes, anti-rabbit and anti-mouse
secondary antibodies (LiCor; Lincoln NE 1:5000) were incubated for 1-hour at
room temperature in 1% NFDM in PBS-T. Membranes were scanned using LiCor
Odyssey Imager and raw intensity for each band was measured using LiCor
Odyssey image analysis software.
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4.2.5 Stereology
Stereological methods will be used for quantification of cells present in the
tissue stained. The tissue will be viewed with an Olympus BX60 microscope and
MBF CX 9000 camera. The tissue is quantified using optical fractionator from
MBF software of Stereo Investigator (Ver.8). TH positive and NeuN positive cells
are quantified within the area of the SN pars compacta (see previous chapter).
The sampling site is customized to count 300 cells per brain. For OX-6 cells CF
is 400 x 300 and CG of 400 x 300 of one in every six sections that includes
beginning to end of the anatomical region of interest.

4.3 Results

4.3.1 AAV-9 Synuclein (WT) leads to loss of TH in SN dopaminergic cells
and an increase in expression of MHC class II in microglia:
In the previous study (Chapter 3) we observed that with the addition of α
synuclein into the SN through the use of AAV9 there was a significant loss of TH
positive cells as compared to the controls. As a role of the innate immune
system has been implicated in the neurodegenerative process and it has been
established that α-synuclein activates microglia (Su, Maguire-Zeiss et al. 2008)
we decided to examine microglial activation in our model. We examined the
expression of MHC class II (OX-6) as an index of activated microglia expression.
We observed that in areas where there was a decrease in TH positive
cells there was also an increase of OX-6 positive staining on the adjacent tissue
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of the same rat. This indicates that there is a correlation between increase of
Ox-6 and decrease in TH positive staining. We also decided to look at the same
area but further away from the needle track and we noticed that there was still an
expression of active microglia in adjacent section of the same rat where there
was intact DA cells in the SN. Rats were treated with a diet supplemented with
spirulina beginning one month prior to the AAV9-α-synuclein insult and continued
one month after surgeries As shown above, we observed a large increase in the
amount of OX-6 positive cells in the SN when the rats were injected with αsynuclein (Fig. 4.1 A) as compared to the control rAAV9-GFP (Fig. 4.1 B). . We
further observed that with the spirulina diet there was a significant decrease in
the OX-6 positive staining in the SN (Fig. 4.1 C) as compared with rats that did
not receive spirulina (Fig.4.1 A) Also the groups that received rAAV9-GFP did
not have an effect on Ox-6 staining regardless of the diet. This indicates that the
rAAV9-GFP used did not stimulate an immune response (Fig. 4.1 D).
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Fig 4.1 A-D
OX-6 positive photomicrographs depicting the effects α-synuclein has on the
activation of microglia. Panel A and B are the control group and on panel A there
is massive expression of active microglia with α-synuclein, on panel B there is no
effect of microglial activation with rAAV9-GFP. Panel C show a decrease in Ox-6
positive staining when fed a diet enhanced in spirulina and again in panel D there
is still no expression of Ox-6 positive cells.
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4.3.2. Effects of injections with GFP after one month of incubation
We decided to look and see if there was any significance between the
injections of AAV9-GFP to make sure that there wasn’t a significant difference
between that diets that would of affected the brain. We did not see a significant
effect with the GFP positive cells between the two diet groups (Fig. 4.2). Also
we wanted to look to see if the same amount of cells were seeded into each
group of rats and we saw that this was the case since there was no significant
different between the groups with the same insult and different tratments. This
also confirms what we see in the photomicrographs (Fig. 4.1 A-D) that the GFP
and the use of AAV9 as a vector did not cause an immunological reaction in this
model. This indicates that GFP had no negative effect in this study and that
spirulina did not ialtered any results.
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Fig. 4.2
Quantification of GFP positive cells in the SN. Using unbiased stereological
methods GFP positive cells where quantified in the SN of one month old
incubation group. No significant effect was seen between the diets or the
injections with GFP.
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4.3.3 Effect of spirulina on α-synuclein in the SN.
Fig. 4.3 A shows α-synuclein immunostaining in the SN of rats after one
month of incubation. Fig. 4.3 B shows the same area in the SN for rats that
receive a diet enhanced with spirulina. We can clearly notice a decrease in the
staining of panel B as compared to how clear and bright the cells look in panel A.
The cells in panel B look more opaque and scattered this could be due to the
effects spirulina has on α-synuclein, since its known for its anti-inflammatory
properties, which α-synuclein tends to challenge in PD.
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Fig. 4.3 A and B
Photomicrographs representing α-synuclein staining in the SN. A comparison
between control diet (A) and a diet enhanced with spirulina (B).
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4.3.4 Quantification of the effects of spirulina on TH positive cells and OX-6
positive cells.
We examined the effect of spirulina 2 weeks after α-synuclein treatment.
We did not observe any significant changes between the groups when we
examined TH positive cells after 2 weeks, we didn’t see a diet effect either after
this time (Fig. 4.4 A). This correlates with the two week data from chapter 3. We
also examined expression of TH positive staining after one month and we saw
that there was a significant decrease in the TH staining in the group that received
the regular NIH-31 diet and had AAV9- α-synuclein as insult. (Fig 4.4B). Even
though is not significant we can see an improvement in the TH cell staining in the
rats that received the diet enhanced with spirulina after 1 month of incubation.
We then quantified the TH cells after 4 month and we saw a decrease in TH cells
after AAV9- α-synuclein and this was reversed significantly with the spirulina diet.
This reflects that there was not an early activation of microglia prior to significant
loss of cells.
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Fig. 4.4B
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Fig 4.4 A-C
Graphs representing TH positive quantification of unbiased
stereological analysis showing no significance after two week of insult
and treatment with spirulina (A). Significant decrease after one
month with AAV9- α-synuclein and improvement with spirulina diet
(B). Also decrease in TH cells after 4 month that was reversed with
the spirulina enhanced diet (C). Asterisk denotes significance.
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4.3.5 Effects of spirulina with NeuN immunoreactive cells.
We next examined the effect of spirulina after AAV9-α-synuclein with
NeuN positive cells to see if we had similar effects as with TH positive staining.
As previously seen with TH positive cells there was no significant cell loss with 2
weeks of incubation this was the same effect we saw with NeuN staining in this
part of the study as well (Fig 4.5 A). In chapter 3 we observed a significant
decrease in TH positive cells after one and 4 months. We saw the same effect
with NeuN positive cell staining here after 1 and 4 month of incubation (Fig 4.5 BC). When rats were fed a spirulina enriched diet there was a neuroprotective
effect due possibly by spirulina anti-inflammatory effect. One possible
explanation for this effect is that spirulina contains phycocyan which has been
shown to inhibit cylo-oxygenase and this would cause spirulina to act as an antiinflammatory ingredient (Shih, Cheng et al. 2009). This effect shows significance
between the diet and the insult these rats received. There is significance
between rAAV9 α-synuclein with regular diet and rAAV9 α-synuclein who
received spirulina. There was no significance between the GFP injections with or
without spirulina.
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Fig. 4.5A
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Fig.4.5 A-C
Fig. A As determined by unbiased stereological cell counting technique,
NeuN+ cells in the substantia nigra pars compacta were counted
indicating no significant decrease of of NeuN+ cells after 2 weeks of
incubation. Fig B Shows significant difference can be seen after one
month of incubation compared to the control group Also, spirulina
supplementation resulted in a significant protection from loss of NeuN+
cells. Fig. C shows significant decrease in the AAV9-α synuclein that
received NIH-31 diet. This effects was significant reversed with spirulina
diet. Asterisk denotes significance (P<0.05
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4.3.6 Effect of spirulina on OX-6 positive staining.
We next examined the effects that α-synuclein had on active microglia
expression using OX-6 as a marker for MHC class II. We observed, as shown
previously after two weeks, there was a no significant loss in TH positive cells
and also there was not an increase in OX-6 positive cells with α-synuclein in
NIH-31 diet . We did noticed that with the spirulina there was a minor decrease
in the OX-6 cell expression with α-synuclein insult, even though is not significant
we can still see a trend(Fig 4.6 A). Here active expression of microglia was
significantly higher than with the other groups. We then look for active microglia
expression after one month and we saw that there was a significant increase with
the AAV9- α-synuclein and NIH-31 diet and this was decreased when spirulina
was given to the treatment group (Fig. 4.6 B).. Here active expression of
microglia was significantly higher than with the other groups.
We were interested then to look at the OX-6 cell expression after 4
months of incubation and we saw the same effect as with the one month group.
AAV9- α-synuclein with NIH-31 diet had an increase in cell expression but this
was seen reversed in the spirulina treated group (Fig. 4.6C). So far we can see
the anti inflammatory effects of spirulina in reducing the expression for active
microglia after one and 4 months of treatment. The cells were preserved with
spirulina, the loss of cells was reversed. We also saw an increase in Ox-6
positive staining in the AAV9- α-synuclein treated rats on the control diet but this
was decreased with spirulina.
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Fig. 4.6 B
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Fig 4.6
As determined by unbiased stereological method there is not significant cell
expression with OX-6 marker after 2 weeks (A). There was a significant cell
expression after one month (B) and 4 months (C). There is also a trend when
spirulina was given since Ox-6 positive staining in decreased in the SN of rats
who received α-synuclein and were treated with spirulina. * Asterisk denotes
significance (p<0.05).
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4.3.7 Microglial activation in correlation to TH positive cell loss.
To investigate the presence of activated microglia we used an OX-6
antibody that detects the expression of MHC class II receptors. We saw positive
OX-6 staining, indicating a significant increase in microglial activation, in the
AAV9-α-syn animals treated with the regular rat chow. Conversely there was a
decrease in OX-6 positive cells in the AAV9 α-syn treated animals that were fed
the spirulina diet when compared to controls (Fig 4.7). Based on this data we
decided to measure the correlation between TH Positive and OX-6 positive cells
to see if microglial activation may have played a prominent role in the loss of TH
cells. These data suggest that the anti-oxidant/ anti-inflammatory actions of
spirulina may afford neuroprotection in an inflammatory environment. There is a
correlation between the decrease in TH+ cells and an increase in OX-6+
microglia. Spirulina allowed for the retention of TH+ cells while decrease OX-6
reactive cells. Spirulina’s anti-oxidant/anti-inflammatory actions may allow for
neuroprotection in an inflammatory environment. Interestingly even with
individual groups there was a significant correlation.
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Fig 4.7
There is a correlation between the decrease in TH+ cells and an increase in OX6+ microglia. Spirulina allowed for the retention of TH+ cells while decrease OX6 reactive cells. Suggesting that spirulina’s anti-oxidant/anti-inflammatory actions
may allow for neuroprotection in an inflammatory environment.
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4.3.8 Effects that spirulina on CX3CR1
We have demonstrated an effect of spirulina on decreasing the numbers
of OX-6 positive mircroglia expression after insult with AAV9- α-synuclein. For
this reason we decided to look at additional markers involved with microglial
function. We examined the CX3CR1 which is a chemokine receptor that when
ligated reduces synthesis of pro-inflammatory cytokines IL1β and TNFα. It also
has been seen at decreased levels during aging. Interestingly we saw that there
was a significant increase in CX3CR1 in all groups treated with spirulina,
independent of α-synuclein treatement. This upregulation was a novel discovery
in our lab. We hypothesize that this may be one mechanism through which
spirulina is acting on the immune system. Fig 4.8 shows a significant increase in
the levels of CX3CR1 with the spirulina diet, an effect that we did not see with
regular diet (NIH-31).
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Fig 4.8
Western blot looking at the expression of Cx3CR1 in the different groups.
Significant increase in the CX3CR1 when a diet enhanced with spirulina was
given. NIH-31 treated rats did not had a significant increase. This indicates the
possible method of action for spirulina’s neuroprotection. Asterisk denotes
significance (p< 0.05). Two way ANOVA analysis.
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4.4 Conclusion
Treatment with spirulina was effective in protecting the loss of TH and
Neun positive cells at both time periods, one and four months, after AAV9-αsynuclein treatment. This treatment also significantly reduced markers of
activation of the innate immune system such as OX6.
After looking at all of the correlation between TH and Ox-6 markers we
decided to look at the effect rAAV9 α-synuclein had after 4 months of incubation.
When we quantified the data we noticed the same effects was seen in the one
month incubation group. When we compared the one month group with the 4
month group we did not see that the lesion had increased in its progression or
microglia expression increased. Everything remained the same for the two time
periods. This could be due to the fact that we were trying to create a partial
progressive lesion mimicking human type and not an 80% cell loss in a short
period of time.
Expression of activated microglial cells is associated with TH positive cells
deficit after the given one month incubation period of α-synuclein induced
expression. This also occurred with the 4 month group, indicating a consistency
in the activation of microglia.
According to our results, we saw that the loss of TH positive cells in the
rats fed the NIH-31 diet was greater than the rats fed the spirulina enhanced diet.
Also, we saw that spirulina reduced the expression of active microglia OX-6
when compared to rats fed NIH-31, and this expression positively correlated to
TH cell loss and NeuN cell loss. Interestingly we noticed that spirulina increased
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the levels of CX3CR1, a chemokine that keeps microglia in a resting state by
decreasing pro inflammatory cytokines. We believe this could be the mechanism
of action of spirulina. This was a novel discovery in our study. We decided to
look at this marker since we know it keeps microglia in a resting state and also it
has been seen in decrease levels in aging. For this reason we decided to look at
it an we were surprised to see that spirulina effects up regulated the CX3CR1
marker expression regardless of the type of insult they received or the different
timelines. With this discovery we can see other areas of research when it comes
to neuroinflammatory diseases and aging.
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CHAPTER 5

CX3CL1 REDUCES NEUROTOXICITY AND MICROGLIAL ACTIVATION IN A
RAT MODEL OF PARKINSON’S DISEASE

5.1 Parkinson’s disease and Fractalkine
Parkinson’s disease (PD) is a neurodegenerative disorder affecting the motor
system including motor coordination and speed as well as producing rigidity and tremor.
The symptoms of PD are mainly due to a progressive loss of dopaminergic neurons
within the pars compacta of the substantia nigra (SNpc). This degeneration decreases
the evels of the neurotransmitter dopamine in the nigrostriatal system. In the past 15

years, an increasing amount of evidence has emerged to suggest that
inflammation may contribute to nigrostriatal pathway degeneration and
accelerate the progression of pathology in PD patients. Within the
microenvironment of the brain, glial cells play a critical role in homeostatic
mechanisms that promote neuronal survival. There is a long history
demonstrating, at least a casual link, in humans between microglia activation and
PD, including early studies, which showed activated microglia in the substantia
nigra of PD patients and people exposed to MPTP (McGeer, Itagaki et al. 1988;
Langston, Forno et al. 1999). The contribution of microglia activation to the
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degenerative process in PD is presently unknown, but is likely to have a
damaging rather than a beneficial role (Block, Zecca et al. 2007).
In animal models that mimic many aspects of Parkinson disease, activated
microglia has been shown capable of damaging and killing neurons (For reviews
on the topic see: (Block, Zecca et al. 2007; Hirsch and Hunot 2009)). However
microglia do not typically kill neurons unless they are activated by a ‘danger
signal’ such as the release of ATP, DNA, or mitochondria from a cell, which can
occur when a cell dies and is not efficiently cleared (Matzinger 2002). While
‘danger signals’ can activate microglia there are also a number of suppressive
signals that neurons use to induce ‘immune tolerance’ to protect the neurons
from being killed. Recent evidence indicates that neurons are not only passive
targets of microglia but rather can control microglial activity. Fractalkine
(CX3CL1) is one of the signals that neurons constitutively express that plays a
‘calming’ role to reduce microglial activation by ligation of CX3CL1 to a G-protein
coupled receptor (CX3CR1) present on microglia. CX3CL1 is a transmembrane
chemokine and exists in both membrane-bound and soluble forms. Its
membrane-bound form displays adhesion properties and consists of an
intracellular domain and a transmembrane domain (Bazan, Bacon et al. 1997;
Pan, Lloyd et al. 1997). Soluble CX3CL1 form results from the cleavage of
membrane-bound CX3CL1 by the metalloproteinase ADAM 10 and ADAM 17
(Garton, Gough et al. 2001; Hundhausen, Misztela et al. 2003).
In contrast to many other chemokines, CX3CL1 binds to only one receptor
(CX3CR1). This receptor responds to membrane-bound CX3CL1 and to the
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soluble form. CX3CL1 acts in vitro as an anti-inflammatory molecule by down
regulating IL-1, TNF- and, IL-6 production (Zujovic, Benavides et al. 2000;
Zujovic, Schussler et al. 2001). CX3CL1 has an essential role in protecting the
brain from a dysregulated microglial response that leads to neurotoxicity
(Cardona, Pioro et al. 2006). Yet, while it is clear that complete loss of CX3CL1
signaling leaves neurons susceptible to microglia mediated neuronal injury and
death, however it is not clear if supraphysiological levels of CX3CL1 would be
neuroprotective. CX3CL1 and the CX3CL1 receptor are normally expressed at
relatively high levels in the brain (Harrison, Jiang et al. 1998; Cardona, Pioro et
al. 2006). It has been shown that there are age related changes in CX3CL1
(Bachstetter, Morganti et al. 2009; Lyons, Lynch et al. 2009), but there is not a
complete loss. Moreover, it is not known, at normal physiological conditions, if
CX3CL1 or the CX3CR1 are in excess. As this signaling pathway is very
important for regulating inflammation in the brain, it is likely that the ligand would
be in excess to ensure tight regulation of the immune response. When neurons
are lost there will be changes to the levels of CX3CL1. Surrounding ‘healthy’
neurons could be left vulnerable to the neuroinflammatory response due to the
altered local CX3CL1 changes Therefore, this study sought to determine if the
CX3CL1 pathway could be a therapeutic target to prevent excessive microglia
activation that contributes to neurodegenerative disease in the 6-OHDA, toxin
induced, model of Parkinson’s disease. The results of this study demonstrate that
even small increases in CX3CL1 can be neuroprotective, by suppressing
microglia activation.
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5.2 Specific material and methods

5.2.1 6-OHDA and fractalkine
All surgical procedures, followed previously described methods (Gemma,
Catlow et al. 2007; Bachstetter, Morganti et al. 2009). Rats were anaesthetized
with isofluorane. Depth of anesthesia was monitored and adjusted as necessary.
All procedures were performed using sterile techniques. Briefly, the head was
incised using a sterile scalpel blade; bleeding was minimized using cotton swabs.
A hole was drilled for placement of a skull screw to be used as anchors for dental
acrylic. A second hole was drilled over the dorsal striatum for placement of a
cannula at the following coordinates: AP=+1.0; ML= +3.0 and V= -4.5. 6-OHDA
(20µg/4µL) was infused at a rate of 0.5µL per minute into the left striatum
(Gemma et al., 2007). Immediately after the 6-OHDA lesion a stereotaxically
implanted cannula (coordinates: AP=+1.0; ML= +3.0 and V= -4.5) was affixed to
the skull by dental acrylic and attached to an osmotic minipump inserted
subcutaneously, for a sustained delivery of saline for 7 days. After the first 7
days, a mid-scapular incision was made and the saline pump was switched for
the treatment pump to deliver 3ng/day (n=5), 30ng/day (n=4), or 90ng/day (n=5)
of FKN or 90ng/day of heat-inactivated fractalkine (n=6) (as a control) for 28 days
into the site of the lesion (Alzet model 2004: pumping rate 0.25 μl/hr (± 0.05
μl/hr); total volume 1.0mL) as previously described (Bachstetter, Morganti et al.
2009). After day 28 the rats were anesthetized and perfused transcardially with
phosphate buffered saline (PBS) followed by 4% paraformaldehyde. Brains were
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then removed and postfixed in paraformaldehyde overnight; they were then
transferred to a 30% sucrose/PBS solution for at least 16 hours. Coronal sections
were cut (40 μm) using a cryostat and the sections were collected and stored in a
cryoprotectant solution at –20°C until processing.

5.2.2 TH Immunohistochemistry
A series of one in six sections was selected that included the anatomical
region of interest of the SN with a random start section for each subject for this
staining. Also 1 in 3 sections were stained for the cavalieri stereology method of
volume analysis for the STR
On day one, the tissue was transfered from cryoprotectant to 0.1MPBS
(pH 7.2-7.5) and washed three times for 10 minutes each on a shaker at room
temperature (RT). Then the tissue was incubated in sodium periodate
(TBS/NaIO4) for 20 minutes at RT (60 rpm). Washed 3 times in 0.1M PBS for 10
minutes each at RT on a shaker and blocked with a PBS-Triton-serum (Normal
Horse serum; Lampire Biological Labs- cat # 7333400) for 60 minutes at RT.
After 1 hour, tissue was incubated with the primary antibody (mouse anti TH,
1:10,000 and 1:1000 for STR; Immunostar cat# 22941) overnight at 4◦C. On day
2 of this protocol, tissue was washed 3 times with PBS and serum for 10 min
each at RT and then. Incubate with secondary antibody (Horse anti mouse1:1000 from Vector cat # BA-2001) for an hour at RT. Then washed again 3
times as previously stated. The tissue is then incubated with ABC solution
(Vector Cat# PK-6100) for 1 hour at RT. and washed with PBS 3 times, then
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incubated with DAB without metal enhancer (Vector Cat# SK-4100) for 2
minutes, washed and mounted on slides, after dehydration the slides are
coversliped.

5.2.3 OX-6 immunohistochemistry
One out of six sections was selected for the SN and one in every third
section was stained including beginning to end of the striatum. After transferring
the tissue from cryoprotectant wash with 0.1M PBS. Incubate the tissue in 40%
Methanol/ peroxide (MeOH) solution for 20 minutes at RT then, wash as
previously stated. The tissue was then blocked with a PBS-Triton-serum (Normal
Horse serum; Lampire Biological Labs- cat # 7333400) for 60 minutes at RT.
Incubated with primary antibody (Mouse anti-RT1B- 1:750 BD cat# 554926)
overnight at 4◦C. On day 2 of this protocol, tissue was wash 3 times with a
solution of PBS and serum for 10 min each at RT and Incubated with secondary
antibody (Horse anti mouse with a dilution of 1:300 from Vector cat # BA-2001)
for an hour at RT. Then wash again 3 times as previously stated. Tissue was
incubated with ABC solution (Vector Cat# PK-6100) for 1 hour at RT. Wash
again with PBS 3 times. Incubated with DAB with metal enhancer (Vector Cat#
SK-4100) for 2 minutes, washed again and mounted slides, dehydrated tissue,
and coversliped.
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5.2.4 NeuN immunohistochemistry
Using one in sixth sections, tissue were transferred from cryoprotectant
into 0.1M PBS that included the whole SN from beginning to end and incubated
in 40% methanol/2% H2O2 solution for 15 minutes at RT; washed with PBS for 3
times at RT. Blocked the tissue with a PBS-Triton-serum (Normal Horse serum;
Lampire Biological Labs- cat # 7333400) for 60 minutes at RT and then incubate
with primary antibody (Mouse anti NeuN 1:1000; Millipore Cat# 3777) overnight
at 4◦C. On day 2, of this protocol, wash 3 times with a solution of PBS and serum
for 10 min each at RT. Incubate with secondary antibody (Horse anti mouse1:300 from Vector cat # BA-2001) for an hour at RT. Then wash again 3 times as
previously stated. Incubated with ABC solution (Vector Cat# PK-6100) for 1 hour
at RT. Washed again with PBS 3 times. Incubate with DAB without metal
enhancer (Vector Cat# SK-4100) for 2 minutes, wash again and mount slides,
dehydrate tissue and coverslip.

5.3 Results:

5.3.1 CX3CL1 protects against 6-OHDA induces dopamine cell loss and
neurodegeneration:
Intrastriatal 6-OHDA induces loss of dopamine terminals in the striatum
and cell loss in the SNpc and is used as model of PD like neurodegeneration.
Figure 1 shows the loss of the TH immunoreactivity in the striatum of rats 5
weeks after an injection of 6-OHDA. PD is a slowly progressing
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neurodegenerative disease, which requires substantial cell loss of the substantia
nigra to occur before clinical symptoms are evident. To determine if the CX3CL1
signaling pathway could be protective during the progressive degenerative phase
of the disease we began a sustained intrastriatal infusion by osmotic minipump of
CX3CL1 beginning one week after the initial insult of 6-OHDA and lasting for four
weeks. Three doses of CX3CL1 (3, 30, or 90 ng/day) were tested in this model
and compared to treatment with heat inactivated (HI)-CX3CL1. As shown in
Figure 5.1, all three doses of CX3CL1 resulted in a marked protection of the TH+
terminals in the striatum. Quantification of the amount TH+ terminals loss showed
that all three concentration of CX3CL1 resulted in a similar 50% reduction in the
size of the TH negative zone (Fig5.1.E). The amelioration of the lesion size by
CX3CL1 was significant for all three doses. There was no difference between the
different doses in the ability to protect the terminal from degeneration.
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Figure 5.1 A-E

CX3CL1 reduces 6-OHDA induced lesion volume in striatum: Photomicrographs
representing TH immunohistochemistry following a 6-OHDA lesion. In the dorsal
striatum a noticeable decrease of TH immunoreactivity is seen in the control
group (HI CX3CL1; A) as compared to the groups who received exogenous
CX3CL1 for 28 days; 3ng (B), 30ng (C) CX3CL1 90ng (D). Bar denotes 0.5mm.
Quantification of the TH negative zone in the striatum of 3-month-old rats as
determined by the Cavalieri method of unbiased stereology, demonstrates
significant decrease in the TH negative immunoreactivity when CX3CL1 was
administered at the different concentrations (3, 30, and 90 ng) for 28 days (E).
The group that received HI-CX3CL1 had a significant larger lesion size. These
findings indicate that CX3CL1 plays a neuroprotective role in the 6-OHDA model
of Parkinson disease. One way ANOVA testing [F (3,19) = 7.149, p=0.0029].
Asterisk denotes significance (* P<0.05) of Tukey post-hoc analysis compare to
HI-CX3CL1 group.
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5.3.2 CX3CL1 suppresses the activation of microglia in the striatum
following a 6-OHDA insult:
Signaling by CX3CL1 to the only known receptor, CX3CR1, has been
shown to be critical for restraining microglia activation. Moreover, in the CNS,
CX3CR1 is only expressed on microglia (Harrison, Jiang et al. 1998; Cardona,
Pioro et al. 2006; Combadiere, Feumi et al. 2007). The CX3CL1effects
demonstrated by CX3CL1 in protecting the TH+ terminals were hypothesized to
occur by suppression of microglia activation. The major histocompatibility
complex II (MHCII) is normally undetectable on microglia. Activation of the
microglia induces MHCII expression, and presumably indicates a detrimental
form of microglia activation. To assess the activation of microglia we stained for
MHCII expression using the antibody OX-6. As shown in figure 5 2, at 5 weeks
after the 6-OHDA insult there was a large volume of OX-6 positive staining in the
striatum of the HI-CX3CL1 treated rats. As can be observed in figure 5.2 B-C,
there was a reduction in MHCII staining in the CX3CL1 treated animals. Using
cavalieri method to assess the volume of MHCII expression we compared the
effect of CX3CL1 in the STR in all of the groups (Fig.5.2E). A significant
decrease in the volume of OX-6 positive cells was found in the rats treated with
30 or 90ng/day of CX3CL1.
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Figure 5.2

CX3CL1 suppresses microglia activation: Micrographs of OX-6 positive cells
(MHCII; a marker for actived microglia) show a large increase in OX-6 staining in
the control treated animals 5 weeks after a 6-OHDA in to striatum (A). Twentyeight days infusion of CX3CL1 3ng (B), CX3CL1 30ng (C), or CX3CL1 90ng (D),
beginning 7 days after the insult with 6-OHDA show a clear reduction in OX-6
staining. Bar denotes 0.5mm. Arrow denotes ameboid microglial cell (Panel A).
Quantification of OX-6 immunoreactivity, by the Cavalieri method, found a
significant decrease in OX-6 expression when exogenous CX3CL1 was
administered (30 ng and 90 ng) as compared to the heat inactivated control (E).
One way ANOVA testing [F (3,19) = 4.172, p=0.0232]. Asterisk denotes
significance (* P<0.05) of Tukey post-hoc analysis compare to HI-CX3CL1 group.
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5.3.3 Neuronal loss and microglia activation in the substantia nigra is
reduced by treatment with CX3CL1:
To assess if this increased TH fiber density in the striatum reflected a
protection from cell death in the substantia nigra TH positive cells were counted
in the SNpc. Treatment with CX3CL1 at 3, 30, and 90 ng of CX3CL1 resulted in
significant protection from loss of TH+ cells compared with HI-CX3CL1 (Fig.5.3E).
To confirm that the loss of TH+ cells reflected cell death, NeuN immunoreactive
cells were also counted in the SNpc (Fig.5.3F). The number of NeuN cells
confirmed the results observed with TH+ immunohistochemistry that the
administration of exogenous soluble CX3CL1 helped protect the cell loss in the
substantia nigra. While CX3CL1 was delivered directly into the striatum,
protection of the terminals in the striatum could result in decreased microglia
activation in the substantia nigra as a secondary interaction of less dying
neurons. Quantification of the number of OX-6 positive cells in the SNpc
confirmed this hypothesis (Fig.5.3G), and indicates that blocking inflammation in
the striatum can decrease the inflammatory cascade in the substantia nigra.
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Figure 5.3

Neurodegeneration is prevented in the substantia nigra: Photomicrographs of
TH immunoreactivity in substantia nigra demonstrate a noticeable decrease in
TH immunoreactivity in the control groups (A) as compared to the groups that
received 3ng (B), 30ng (C) and 90ng of CX3CL1 (D). Bar denotes 0.2mm. (E)
Quantification of the number of TH+ cells in the substantia nigra shows a
significant decrease of TH immunoreactivity in the substantia nigra of animals
who receive HI CX3CL1 (control treatment) but this affect was reversed when
animals received 3, and 90ng exogenous soluble CX3CL1 through and osmotic
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minipump for 28 days one week after a lesion with 6-OHDA. One-way ANOVA,
[F (3,19) = 9.498, p= 0.0008]. Asterisk denotes significance (* P<0.05) compare to
HI-CX3CL1 group; † denotes significance († P<0.05) compare to 90ng CX3CL1
group as determined by Tukey post-hoc analysis. (F) Quantification of NeuN
(neuronal nuclei marker) immunohistochemistry in substantia nigra shows a
significant decrease in the HI-CX3CL1 control group as compared to the groups
of animals treated with 3ng and 90ng of CX3CL1. One-way ANOVA, [F (3,19) =
7.359, p= 0.0026]. Asterisk denotes significance (* P<0.05) of Tukey post-hoc
analysis compare to HI-CX3CL1 group. (G) An increase in the number of OX-6+
cells in substantia nigra was found in the HI-CX3CL1 control group. CX3CL1This
was significantly decreased by all three doses of CX3CL1. One-way ANOVA,
[F (3,19) = 19.04, p<0.0001]. Asterisk denotes significance (* P<0.05) compare to
HI-CX3CL1 group by Tukey post-hoc analysis.
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5.4 Conclusions
In conclusion, this study demonstrates that the CX3CL1/CX3CR1 axis is
an important target for drug discovery to modulate microglia activation in PD.
Therefore, in the future it will be important to develop selective small-molecule
agonists for CX3CR1 that are orally bioavailable and brain-penetrant. However,
more work is also necessary to determine the role of CX3CL1 and CX3CR1 in
normal physiological conditions, as well as, in models of neurodegenerative
diseases.

92

CHAPTER 6

DISCUSSION

6.1 Parkinson’s disease and α-synuclein
Parkinson's disease being the second most common neurodegenerative
disorder has called the attention of many scientists as well as with us. This
debilitating disorder is characterized by the loss of DA cells, which control motor
movements of the body. There are many factors involved in the disease that are
being studied currently since there is no known cause for the disease. There are
many characteristics involved with the pathology of PD, one of which is the
formation of lewy bodies which are saclike structures filled with α synuclein a
known marker for PD. α synuclein and its different mutations and
overexpressions have been one of the characteristic hallmarks of sporadic PD.
When the α-synuclein gene becomes activated, and the protein that is formed
fails to fold properly due to a mutation in the gene, then the protein aggregates
forming oligomers and fibrils.
There have been many models mimicking PD that show the progression
of the disease such as 6-OHDA model and MPTP model. There are other
models showing different mutant forms of α synuclein also since this and non
amyloid forming oligomer that in nature is found unfolded therefore its very prone
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to misfolding. In our study we examined a model close to what is seen
happening in the human brain as the disease progresses. We used a model of
human wild type α-synuclein tagged to an AAV as a vector to deliver and over
express α-synuclein in the SN. In our study we examined different timelines to
try and understand the steps in the progression of PD and the key ingredients
that go along with it. Other scientists have also used the AAV method of
transduction but mainly with serotypes 2/5. In our case we chose serotype 9
since it is neuronal specific and has high transduction efficiency after just a single
application. In a study by Gorbatyuk (2007) this group used serotype 2/5 to
transduce wild type human α synuclein, and two mutated versions of it and they
noticed that there was an effect in one of the mutated forms (S129A) and the wild
type of human α synuclein. This group also verified the transduction and it
worked well but for only 8 weeks after the insult. Interestingly they also saw
immediate cell loss with the mutant form and not with the wild type, that they saw
an effect later on. They also looked after 26 weeks and they noticed that the wild
type lost the same amount of cells that were lost in the 8 weeks mutant group. In
our study we saw an effect with the AAV9 human wild type α synuclein 4 months
after the insult. This demonstrated the effect of the AAV9 and also the human
wild type α synuclein which correlates to what they saw in their study when TH
positive cells were lost as compared to their control. Also shows a slower
progression possibly similar to that seen in human PD.
After comparing our data with other published literature we can conclude
that we have a viable model of PD. Further studies are needed to determine if
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with a longer incubation time we get a more progressive deterioration instead of
a partial cell loss. In a paper by (Eslamboli, Romero-Ramos et al. 2007) they
followed marmoset monkeys for one year after transduction with AAV-GFP, AAVhuman wild type α-synuclein and AAV-A53T mutated α-synuclein. They found
that TH fiber terminals in the striatum were partly lost and the ones that remained
were dystrophic (Eslamboli, Romero-Ramos et al. 2007). They also saw
intracellular aggregates after one year. This shows that perhaps the α-synuclein
incubation period has to be for a longer period of time to cause a substantial
effect or a greater percentage of DA cell loss.
Our study was also used to determine if the oligomeric formation of αsynuclein was the cause of the loss in DA cells. In our study we tested to
determine if the levels of α-synuclein were human wild-type α-synuclein or
endogenous rat α-synuclein. Interestingly we saw that we had trimeric formation
in the control group which led us to believe that there is expression of
endogenous α-synuclein rather than human wild type or that the human wild type
was small enough to not be detected. This was done after 4 months of
incubation with α-synuclein. In a study by Outeiro (2008), in vitro study was
performed where cells were transfected through Superfect method, a reagent of
spherical architecture that branches and binds negatively charge particles that
bind to cell surface and enter through non specific endocytosis. This was tagged
with α-synuclein since oligomeric species have been identified in living cells to
this date. Twenty four hours after transduction they observed that protein
complementation occurred when α-synuclein interacted with α-synuclein
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construct rather than the untagged α-synuclein species. This indicates that αsynuclein indeed tends to oligomerize with other α-synuclein molecules, perhaps
with some sort of seeding mechanism. In this investigation they used the
biomolecular fluorescent complementation method to determine the toxicity in αsynuclein oligomers. They found that the stabilization of α-synuclein was more
toxic when the oligomeric form was created (Outeiro, Putcha et al. 2008).
α-synuclein oligomeric species are toxic but α-synuclein also activates
microglia. In our study we saw that there was an increase in activated microglia
when α-synuclein was administered. We believed that α-synuclein triggers the
activation that leads to cell death in the SN and the STR in PD. In a study by Su,
et al. 2007, they used a transgenic mouse model over expressing human wild
type α-synuclein. They observed an increase in Iba 1 positive cells, a marker
that indicates the activation of microglia, in the transgenic α-synuclein as
compared to the non transgenic mice at one month of age. They also saw an
increase in expression for the Iba1 marker in the SN and TNF- α in both the STR
and SN (Su, Maguire-Zeiss et al. 2008). This is similar to the effect we had with
α-synuclein and the increase in OX-6 positive cells after one month of incubation
with the rAAV9 α-synuclein. We also noticed the loss of DA cell correlated to the
increase in OX-6 positive marker. This led us to believe that active microglia is
indeed involved in the loss of TH positive cells.
Zhang (2005) investigated the possibility that nigral cell loss in vitro was
due to the active form of microglia. He found that extracellular human αsynuclein that was aggregated activated microglia and increase dopaminergic
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neurodegeneration in mesenphalic neuron-glia cultures. This also activated
NADPH oxidase producing ROS (Zhang, Wang et al. 2005).
In our study we used as a treatment spirulina, blue-green algae, that has
antioxidant and anti-inflammatory properties that challenged the effects caused
by α-synuclein in DA cells. Natural products such as spirulina are rich in
antioxidants that helps get rid of ROS and NO species that damage our systems
as we get older. Spirulina is considered an instant antioxidant because of its
ORAC value (61900 µMol), which determines how efficient an antioxidant is
when it comes to getting rid of ROS. It also contains and important key
ingredient called phycocyanin, a biliprotein that has antioxidant and antiinflammatory properties. Our results demonstrated that spirulina help protect TH
and NeuN positive cells from dying after one and four month of incubation with αsynuclein.
A very interesting and novel discovery was that we saw that spirulina
increased the levels of CX3CR1, a chemokine called fractalkine, as compared to
the control groups that were not fed a diet enhanced with spirulina. We believe
that this could be the mechanism of action of spirulina in the SN when αsynuclein was injected. Since spirulina is also an anti-inflammatory it could
decrease microglial activation through the CX3CL1/CX3CR1 communication or it
can help transition better toward a resting microglia.
6.2 CX3CL1/CX3CR1 and inflammation
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Another study sought to determine if the CX3CL1/CX3CR1 axis would be
amendable to therapeutic intervention in a disease relevant animal model with a
known inflammatory component as part of the neurodegeneration. The results of
this study lend support to an important role of CX3CL1 in maintaining immune
tolerance in the CNS. Following treatment with CX3CL1 neuronal protection was
found that correlated with a reduction in microglia activation. Since microglia are
the predominant cells in the CNS that express the CX3CL1 receptor, the effects
of CX3CL1 are most likely a direct effect on microglia activity (Harrison, Jiang et
al. 1998; Cardona, Pioro et al. 2006; Combadiere, Feumi et al. 2007). The state
of microglia was assessed by the expression of MHCII, which is an often-used
maker of a classical (M1) proinflammatory state of activation. However, it should
be noted that in this study we can only infer from the changes in MHCII
expression that CX3CL1 exerted the effects by reducing inflammation, as no
direct cytokine measurements such as levels of IL-1 or iNOS were made.
CX3CL1/CX3CR1 is important for suppressing the production of TNF, IL-1, IL6 and INOS (Zujovic, Benavides et al. 2000; Mizuno, Kawanokuchi et al. 2003;
Cardona, Pioro et al. 2006); therefore, this effect of CX3CL1 to reduce cytokines
and alter microglial phenotype away from M1 is the most likely interpretation of
the data. There is a possibility that cannot be excluded from the results of this
study, that exogenous CX3CL1 is having effects on cells other than microglia.
CX3CR1 is expressed on a subset of dendritic cells and natural killer cells,
peripheral blood monocytes and tissue macrophages (Jung, Aliberti et al. 2000).
In vivo neurons do not appear to have detectable levels of CX3CR1 (Cardona,
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Pioro et al. 2006; Combadiere, Feumi et al. 2007), so while effects on other
subsets of immune cells can not be ruled out, it is very unlikely that there is a
direct effect of CX3CL1 on neurons.
An unexpected finding of this study was the lack of a dose response. A
slight dose response was seen in some of the measurements, but a significant
difference between the different treatment doses was not found. It is possible that
the range of doses of CX3CL1 chosen in this study were too narrow to
demonstrate a dose response. A second possibility for the lack of the dose
response is that this signaling pathway, which is tonically activated during normal
physiological conditions, has only a limited extra capacity to suppress glia
activation. Therefore at doses above 3ng/day of CX3CL1 there is an excess of
CX3CL1 to the amount of receptor available. It has been previously shown that
by 7 days after a MPP+ lesion in rats there is an increase in CX3CR1 protein
levels in the substantia nigra; however, similar quantification was not made of
CX3CL1 (Shan, Hong-Min et al. 2009). It is therefore unknown if a
commensurate change in CX3CL1 is also found. Our results would suggest there
is an increase CX3CR1 expression without a parallel increase in CX3CL1,
leading to an imbalance in the CX3CR1/CX3CL1 axis. This imbalance is akin to
what is seen in the CX3CR1 KO mice where disruption in the CX3CR1/CX3CL1
axis leads to neurotoxic inflammation (Cardona, Pioro et al. 2006).
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A final possibility for the lack of a dose response could be due to a floor
affect. Such that, 50% of the lesion occurs by 7 days before CX3CL1 treatment
began, and this primary neurodegeneration cannot be reversed by CX3CL1
treatment; however, further neurodegeneration can be blocked by CX3CL1
treatment. We have previously observed in this model that there is a late phase
of microglial activation that continues to increase from 1 to 4 weeks following the
lesion and that if we block this late phase of inflammation we get neuroprotection;
however, if we block the initial inflammation we can worsen neurodegeneration
(Stromberg, Gemma et al. 2005; Gemma, Catlow et al. 2007). Nevertheless, all
of the different concentrations of CX3CL1 showed neuroprotection in this
Parkinson disease relevant model. This suggests that the communication
between neurons and glial cells may play a role in Parkinson disease
neurodegeneration.
Several reports have shown that CX3CL1 expression decreases during
aging, and this decrease correlates with increased inflammation (Bachstetter,
Morganti et al. 2009; Lyons, Lynch et al. 2009). Consequently, changes in
CX3CL1 could be important for the dysregulation of microglia in the age-related
neurodegenerative disease. Interruption of the CX3CL1/CX3CR1 axis by genetic
deletion causes neurodegeneration following stimulation with lipopolysaccharide,
MPTP, or SOD1 mutation (Cardona, Pioro et al. 2006). Finally, a large singlebolus of CX3CL1 injected into the substantia nigra has been shown to induce a
Parkinson disease like symptoms or even cause death. However, it should be
noted that the control for this injection of CX3CL1 was normal saline. It is
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therefore, unknown if the effects seen are due to the injection of a large amount
of recombinant protein, the bovine serum albumin that was used as a carrier for
the CX3CL1, or if the effect is indeed specific to CX3CL1 (Shan, Hong-Min et al.
2009).

6.3 Conclusion
With this study we have contributed with knowledge about the effects of αsynuclein and the use of a vector that successfully delivered the protein of
interest to the area we were studying for this disease. Also we had different time
lines that allowed us to study further the progression when we used a human wild
type of α-synuclein to be as close as we can to a human even though we used
rats for this study. For this part of the study we could take our time to study
further the progression of PD within 4 months of incubation, we did saw a lesion
and we also saw the involvement of activated microglia. Therefore we cannot
discard the fact that our own immunity plays a role in this neurodegeneration.
We also can see that there are more studies necessary to understand further the
progression of this disease since we know that α-synuclein is a nuclear protein
but somehow it is also involved in the activation of microglia. We could speculate
that the effects of the aggregation of microglia disrupts the integrity of the cell
and this causes an immune response to get rid of the factor causing the
inflammation or it could be that α-synuclein does enter other cells and spreads
the inflammation further. There is still much research needed in this area so we
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can understand better the activation of microglia caused by α-synuclein and its
relationship. We have given the starting point of many scientist with our
discoveries and the fact that the immune system and proinflammation is involved
in many diseases not just neurodegenerative one.
We where also very thrilled to discover the effects that spirulina had on
decreasing the expression of activated microglia in all the groups of 1 and 4
months. This effect may be due to the novel discovery that spirulina upregulates
CX3CR1 expression on microglia. This may be the mechanism of action of
spirulina modulating the immune system. Through this discovery we have open
the door to many possibilities with the mechanism of action of spirulina. There
has already been many studies of the importance with CX3CL1/CX3CR1 axis in
controlling activated microglia, but with the spirulina discovery we can target a
specific mechanism and the key factors involved in this communication.
We also saw the effect of exogenous administration of CX3CL1 on a 6OHDA model. CX3CL1 decrease the expression of activated microglia after 28
day of administration. Even though we didn’t see a dose effect we had a
significant decrease in activated microglia that demonstrated to improved the
area of interest and helps protect the DA cells affected by 6-OHDA lesion. By
looking at all this we can say that in this study we saw neuroprotection with
spirulina, decrease of activated microglia with exogenous administration of
CX3CL1, and upregulation with CX3CR1 and spirulina. Here we can show a
starting point for many scientist using natural products to modulate and improve
the pro inflammatory effects seen in neurodegenerative diseases.
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Currently there are many treatment options for PD in humans, through the
addition of exogenous use of DA, but there isn’t a cure or a preventive method to
stop this disease. In our lab not only did we created a viable model with the slow
progression mimicking that of the human form but we also found some
preventive mechanism through the use of natural products like spirulina. With
this we have impacted the field with a simple natural product accessible to
everyone regardless of their economical status. This is a good and natural
preventive method also we could observe the effect this natural product had on
the immunity in a model of PD. We saw an upregulation of one of the important
receptor found in microglial cells that is also seen at decrease levels in aging
leading to chronic microglial activation. With this product we can upregulate
CX3CR1 during aging providing a balance between pro inflammation and antiinflammation that fails during aging. Also, this product not only served as an antiinflammatory but it also helps protect DA neurons in the SN as well. Also during
an inflammatory response and neuronal death there is an increase in ROS and
this migh of also have been decreased through the antioxidant properties seen in
spirulina, perhaps this is how it serve as neuroprotective. Spirulina improved the
environment surrounding the cells that could have been exposed to
neurodegenerative agents. These findings help make a connection between
natural therapeutics for prevention of neurodegeneration and also it shows that
maybe supplementing the brain with CX3CL1 can improve the brain as we age
not only for PD but for other neurodegenerative diseases where inflammation
plays a major role.
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